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1. Introduction 
1.1  MHC class I antigen presentation pathway 
MHC class I molecules present peptides on the cell surface for surveillance by 
cytotoxic T lymphocytes (Gromme and Neefjes, 2002; Pamer and Cresswell, 1998). This 
antigen presentation pathway plays a central role in the cellular immune response to viral 
infected cells. The processes involved in conventional MHC class I antigen processing and 
presentation are depicted in Fig. 1-1. 
In general, MHC class I molecules present peptides derived from endogenous 
antigens, although exogenous antigens were also shown to be presented by MHC class I 
molecules on the cell surface of phagesomes or dendritic cells in very recent studies 
(Ackerman et al., 2003; Guermonprez et al., 2003; Houde et al., 2003). Degradation of 
 
 
Figure 1-1. MHC class I antigen presentation pathway (Abele and Tampé, 1999). Endogenous
antigens are degraded by the proteasome into short peptides. These peptides are transported into
the ER lumen by TAP. In the ER, newly synthesized MHC class I heavy chains assemble with
β2m and peptide. This process involves transient interaction with calnexin, calreticulin, ERp57,
tapasin and TAP. Upon peptide binding, the MHC complex is released from the ER and
transported to the cell surface via the secretory pathway. Chapter 1    Introduction 
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cytosolic antigens is essential for generation of MHC class I-presented epitopes. This 
process is mainly mediated by the proteasome complex (Bochtler et al., 1999; Rock and 
Goldberg, 1999). The proteasome contains a barrel-shaped 20S core particle that is 
proteolytically active and can degrade proteins in an ATP-independent fashion (Dick et al., 
1994; Eggers et al., 1995). Most intracellular protein degradation, however, appears to be 
mediated by a larger protein complex that consists of the 20S core decorated by two 
additional 19S regulatory subunits, forming the 26S particle. The size of the peptides 
produced by proteosome distributes from 3-30 residues with an optimum length of 6-11 
residues (Ehring et al., 1996; Kisselev et al., 1999). Interferon-γ stimulates the formation of 
the so-called immunoproteasomes (Akiyama et al., 1994; Fruh et al., 1994; Gaczynska et 
al., 1994; Nandi et al., 1996). This subpopulation of proteasomes cleaves after hydrophobic 
and basic residues in higher efficiency and increases the production of peptides that favor 
binding to MHC class I molecules (Aki et al., 1994; Ustrell et al., 1995). Although 
proteosome-dependent degradation of antigens contributes the majority of peptides for 
assembly with MHC class I molecules, there is also strong evidence that MHC class I can 
present peptides produced in the ER (Hammond et al., 1995; Henderson et al., 1992). 
Peptides produced in the cytosol must pass through the ER membrane before they 
can be loaded onto the MHC class I molecules. This process is mediated by the transporter 
associated with antigen processing (TAP) (Abele and Tampé, 1999), which will be 
discussed in detail later. MHC class I molecules consist of a glycosylated transmembrane 
heavy chain (45 kDa) noncovalently associated with a 12 kDa soluble protein, β2m, and a 
short peptide usually of 8-10 amino acids. Binding and presentation of peptides by MHC 
class I molecules are inextricably related to their structure (Madden, 1995). The heavy 
chain harbors three domains (α1-α3). α1 and α2 domains consist of two α-helices resting 
on a sheet of eight β-strands, forming the peptide-binding groove. The N- and C- terminal 
residues of the peptide are anchored to the opposite end of the peptide-binding groove via 
multiple hydrogen bonds and salt bridges, leaving the side chains of the central portion 
pointing outside the groove. Nevertheless, exceptions have also been reported that one or 
both ends of peptides can extend outside of the peptide-binding groove (Collins et al., 
1994; Urban et al., 1994).  
MHC class I molecules must fold into their native conformation in order to 
overcome ER quality control and exit ER for cell surface presentation. Many chaperones Chapter 1    Introduction 
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are responsible for the correct assembly of MHC class I complexes (Paulsson and Wang, 
2003). The newly synthesized MHC heavy chain is first bound to calnexin which ensures 
the proper folding and assembly of the MHC, thereby reduces its degradation (Hammond 
et al., 1994). Subsequently, β2m associates with the heavy chain, and calnexin is exchanged 
for calreticulin (Peterson et al., 1995). A protein disulfide isomerase, ERp57, is believed to 
play a role in the formation of disulfide bonds of MHC class I molecules (Lindquist et al., 
1998; Morrice and Powis, 1998). The association of the MHC class I- β2m-calreticulin 
with TAP is bridged by tapasin (Sadasivan et al., 1996). The TAP, tapasin and MHC class 
I molecules, together with other chaperones (e.g. ERp57), form the multi-subunit peptide 
loading complex (PLC) in the ER membrane, which facilitates the loading of peptides onto 
MHC class I molecules (Hughes and Cresswell, 1998; Williams et al., 2002). Binding of a 
peptide is essential for the stability and transport of MHC class I molecules from the ER to 
the cell surface. Following peptide binding and release from the ER, MHC class I 
complexes are transported to the cell surface through the Golgi apparatus and the trans-
Golgi network (TGN). At the plasma membrane, MHC class I molecules display their 
antigenic peptides for immune surveillance by cytotoxic T-lymphocytes (CTLs). Under 
normal circumstances, T-cell receptors (TCR) of CTLs do not recognize complexes 
containing “self” peptides. However, during viral infections or malignant transformations, 
a different spectrum of peptides is displayed by MHC class I molecules. T cells bearing the 
appropriate TCR will then recognize the peptide-MHC class I complex and eliminate 
diseased cells. 
1.2  Overview of ABC transporters 
The ATP-binding cassette (ABC) transporter superfamily contains membrane 
proteins that translocate a wide variety of substrates across biological membranes. 
Members of this family not only accomplish the uptake of nutrients but also are involved 
in a large variety of processes, such as signal transduction, protein secretion, drug and 
antibiotic resistance, antigen presentation, bacterial pathogenesis and sporulation (Higgins, 
1992; Schneider and Hunke, 1998). ABC transporters have been identified in all organisms 
(bacteria, archaea and eukarya), and might thus be considered as an ancient protein device 
for solutes to pass through the lipid bilayer against a concentration gradient.  Chapter 1    Introduction 
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Typically, an ABC transporter is composed of four modules: two transmembrane 
domains (TMD), with each domain spans the membrane six times, and two nucleotide-
binding domains (NBD) (Higgins, 1992). In eukaryots, the modules are mostly fused to 
yield a single polypeptide chain, while bacterial ABC transporters are built up from 
individual subunits (Fig. 1-2) (Higgins, 1992). In the bacterial importers, an additional 
substrate-binding protein with a high specificity for its solutes is generally presented in the 
transporter machinery. The NBDs of ABC transporters always contain two highly 
conserved motifs: Walker A (GxxGxGKT/S; x: any residues) and Walker B motifs 
(hhhhD; h: any hydrophobic residues) which are also present in other ATPases. In addition 
the NBDs also harbors the third characteristic sequence LSGGQ, which is specific to the 
ABC transporter family and termed C-loop or signature motif. By these criteria, a few 
proteins containing these three motifs have also been recognized as typical ABC proteins. 
 
Figure 1-2. Organizations of four-domain structure in ABC transporters (Schmitt and
Tampé, 2000). In bacterial import systems, the four domains are usually formed with separate
domains (HisP). In some cases either TMDs or NBDs are fused (Flu, Rbs). The extracellular
substrate-binding proteins (J, B, D) unique to this subclass are required for efficient uptake of
the diluted solutes in the environment. In eukaryotic systems, four domains are generally fused
into a polypeptide chain, such as Pgp and CFTR. In CFTR, an additional regulatory domain
(R) is located between NBD1 and the following transmembrane domain. In some cases, two
half transporters form a full functional complex as a heterodimer (TAP1/TAP2) or
homodimer. Chapter 1    Introduction 
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These proteins usually do not have a transmembrane domain and serve other functions. In 
contrast, the TMDs generally share little sequence homology among different ABC 
transporters and are specialized for the binding and translocation of their different 
substrates.  
ABC transporters work unidirectionally. In bacteria, they are predominantly 
involved in the import of essential compounds (sugars, vitamins, metal ions, etc). In 
eukaryotes, most ABC transporters move compounds from the cytoplasm to the outside of 
the cell or into an intracellular compartment. Most of the known functions of eukaryotic 
ABC transporters involve the shuttling of hydrophobic compounds either within the cell as 
part of a metabolic process or outside the cell for transport to other organs or secretion 
from the body. 
1.2.1  Structure of ABC transporters 
ABC transporters are large membrane proteins. Earlier efforts have focused on 
determining the structure of the cytosolic soluble NBD. The first high resolution X-ray 
crystal structure emerged in 1998, which was the NBD of HisP, a histidine permease 
 
Figure 1-3. Structure of nucleotide-binding domain of ABC transporter. A, Structure of
HisP monomer (Hung et al., 1998). The arm I contains the Walker A and Walker B motifs.
Arm II contains mainly α-helices. α-Helices are shown in orange and β-sheets in green. The
location of conserved motifs are indicated by different colors: Walker A, red; Walker B, blue;
C-loop, cyan. The bound ATP is in ball and stick presentation. B, Structure of Rad50 dimer
(Hopfner et al., 2000). Two monomers are orientated in a “head-to-tail” conformation. Two
ATPs are sandwiched between the Walker A and B motifs from one domain and C-loop from
the opposite domain. Chapter 1    Introduction 
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(Hung et al., 1998). The HisP NBD monomer reveals a two-domain architecture, which are 
approximately perpendicular to each other (Fig.1-3A). Domain I mainly consists of α/β 
structure, containing the Walker A and B motifs and the helical domain II, harbors the 
signature motif. Two other conserved motifs, namely the Q-loop and the H-loop, are 
located at the interface of the two arms. Binding of a nucleotide is mainly contributed by 
the interaction between the phosphate moiety and the Walker A motif as well as the 
aromatic ring and the conserved tyrosine through π-π stacking. The crystal structure was 
reported as a dimer with the C-loop facing outward. Since then, a number of isolated 
NBDs have been crystallized in monomeric or dimeric conformation (Diederichs et al., 
2000; Gaudet and Wiley, 2001; Hopfner et al., 2000; Karpowich et al., 2001; Smith et al., 
2002b; Yuan et al., 2001). Although the structure of all monomers is very similar, 
publications about the NBD dimers introduced a controversial discussion about the dimer 
interface (Diederichs et al., 2000; Hopfner et al., 2000; Zhou et al., 2000). Recently, Hunt 
and co-workers reported MJ0796 structure from Methanoccocus janaschii (Smith et al., 
2002a). In the crystal structure, the mutated ABC domain adopted a dimer interface that is 
identical to the one in Rad50 (Fig. 1-3B) showing a head-to-tail orientation. Within the 
dimer, two ATP molecules were sandwiched between the Walker A motif from one NBD 
and the signature motif from the other NBD. This dimer interface gained more support 
from the second MalK structure (Chen et al., 2003a). Further evidences also came from 
biochemical data obtained from MalK and Pgp (Fetsch and Davidson, 2002; Loo et al., 
2002). Thus, the current established belief is that a sandwich dimer with a head-to-tail 
orientation forms during the transport process, in which key residues of both monomers 
participate together in binding and hydrolysis of each ATP (Schmitt and Tampé, 2002). 
Substrate transport through the biological membrane by ABC transporters is a 
complex process including the communication between the substrate-binding site and the 
NBDs as well as the crosstalk between the two NBDs. Recently, the structures of two full 
length ABC transporters provide detailed information about the domain-domain 
interactions (Fig. 1-4) (Chang and Roth, 2001; Locher et al., 2002). MsbA from E. coli, a 
lipid flippase, is a close homolog to mammalian P-glycoprotein. MsbA was crystallized as 
a homodimer. Each monomer contains six transmembrane α-helices, which confirms the 
commonly proposed six-helices organization of the transmembrane domain of ABC 
transporters. The transmembrane domain has a cone-like structure with the top of the cone Chapter 1    Introduction 
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pointing out of the cell. This structure is open at the cytoplasmic side of the membrane. 
The structure also shows a central chamber, which is easily accessible by substrates from 
the inner leaflet of the membrane, while excluding substrate from the outer leaflet. A large 
part of the NBD is invisible in this structure. In addition to the TMD and the NBD, a third 
domain was identified. The so-called intracellular domain (ICD) is composed of α-helices 
and located between the NBD and TMD. This arrangement led to the assumption that the 
ICD acts as a transducer unit, which transmits signals of nucleotide or substrate binding 
between the NBD and TMD. BtuCD, a protein mediating vitamin B12 uptake in E.coli, is 
the second ABC transporter that has been crystallized. It also shows a dimer structure, 
however, the transmembrane structure is composed of 10 helices instead of 6 helices per 
monomer. A large water-filled channel is formed by these 20 helices, which is closed on 
the cytoplasmic side. The ICD structure in MsbA has not been observed in the BtuCD, 
while the NBD directly interacts with TMD through so-called “L-loop”, which is located 
between transmembrane helices 6 and 7. This loop folds into two helices and adopts an “L” 
shape, the sequence of which coincides with the “EAA” motif found in many bacterial 
ABC transporters (Mourez et al., 1997). The interaction between the NBDs resembles that 
 
 
Figure 1-4. Structure of full length ABC transporters. A, Structure of MsbA (Chang and
Roth, 2001). The ICD is highlighted in white and the white lines indicate the putative
position and dimension of the lipid bilayer. B, Structure of BtuCD (Locher et al., 2002).
Walker A and C-loop sequences are highlighted in white and labeled. The ligand,
cyclotetravanadate, is shown in ball-and-stick representation.  Figures were adapted from
(Schmitt and Tampé, 2002). 
 Chapter 1    Introduction 
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of Rad50 and MJ0796 EQ dimers. The structure of the two ABC transporters indicates that 
diversity in TMD packing might generally exist in ABC transporters in order to cope with 
a large variety of substrates and the communication between the TMD and NBD might be 
also different between the exporters and importers (Schmitt and Tampé, 2002). 
1.2.2  Transport mechanism of ABC transporters 
ABC transporters mediate the translocation of a large variety of solutes across the 
biological membrane. The detailed mechanisms by which ABC transporters move solute 
across the cell membrane are still unclear (Higgins, 2001). However, it is believed that 
substrate binding induces a conformational change in the TMDs which is then transferred 
to the NBDs to trigger ATP hydrolysis (Higgins, 2001). ABC transporters contain two 
nucleotide-binding domains, both of which are required for function. It is not fully 
understood why ABC transporters need two NBDs in one transport machine. An even 
more complicated question is how the two NBDs coordinate with each other to energize 
the transport event. Two representative models have been proposed based on the present 
findings: 
In the case of the well studied ABC transporter Pgp, it is supposed to operate in an 
alternative manner (Sauna and Ambudkar, 2001; Senior et al., 1995). In this model, both 
NBDs are capable of binding and hydrolyzing ATP (Urbatsch et al., 1995a). There are two 
ATP hydrolysis events in one single turnover. The transport cycle is initiated by ATP 
binding to one of the randomly chosen NBD, preventing the other one from doing so. The 
second ATP binding and hydrolysis event can only occur after the hydrolysis of the first 
bound ATP. In other words, two ATP hydrolysis events occurred alternatively at each 
domain, which are functionally equivalent. Several observations provide strong support for 
this model: (i) the N- and C-terminal NBDs of Pgp have similar ATP binding properties 
since they are labeled with 8-azido-ATP to the same extent (Senior, 1998; Senior et al., 
1998); (ii) vanadate trapping experiments showed that only one mole of MgADP was 
bound per mole of Pgp after hydrolysis of azido-ATP (Urbatsch et al., 1995b). The same 
stoichiometry was also found in maltose transport system (Chen et al., 2001; Sharma and 
Davidson, 2000); (iii) in addition, trapping of either ATP-binding site in the transition state 
prevents the second site from turning over. A close homologue to Pgp in Lactococcus 
lactis, LmrA seems also to act in an alternating fashion like a two-cylinder engine (van Chapter 1    Introduction 
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Veen et al., 2000). However, the sequential mechanism of ATP binding from this model is 
challenged by a symmetric dimer structure containing two bound ATP molecules (Smith et 
al., 2002b). 
By contrast, two NBDs of several ABC transporters, including MRP1, SUR1, 
CFTR and TAP do not seem to be functionally identical. In those complexes, nucleotides 
interact differently with the two NBDs (Aleksandrov et al., 2002; Hou et al., 2000; 
Karttunen et al., 2001; Matsuo et al., 1999). Mutations of the consensus Walker motifs in 
the two NBDs of MRP1 and TAP have different effects on substrate transport (Alberts et 
al., 2001; Daumke and Knittler, 2001; Lapinski et al., 2001). In contrast to Pgp, positive 
cooperativity in ATP binding has been observed for MRP1 (Hou et al., 2000; Hou et al., 
2003). On the other hand, sequence difference in the conserved C-motifs between the two 
NBDs from these ABC transporters may also provide a hint to unequal functions. In the 
second nucleotide-binding domain, two critical residues (leucine and glycine) in the 
common signature motif (LSGGQ) are often substituted by other amino acids forming an 
irregular sequences xSxGQ. Therefore, this type of C-signature motif is usually called a 
“degenerated C-loop”. Based on these, it was proposed that one NBD in the complex 
hydrolyses ATP to provide the energy for translocation, while the other one only binds 
ATP as a regulatory domain (Yang et al., 2003).  
The NBDs of ABC transporters presumably undergo the following steps within one 
ATP hydrolysis cycle: (i) ATP binding, followed by (ii) ATP hydrolysis, (iii) dissociation 
of Pi, (iiii) release of ADP (Balakrishnan et al., 2003; Schmitt and Tampé, 2002). Three 
conformational stages are generated following the actions of the NBDs: ATP-associated 
state, a short-lived transition state in which both ADP and Pi remain bound and an ADP-
bound state. It is not known at which stage of the transport cycle the energy is converted 
into the power stroke, which finally shuttles the substrate across the membrane. In other 
words, is the binding of ATP, its hydrolysis or the dissociation of inorganic phosphate or 
ADP the triggering step? 
1.3  Transporter associated with antigen presentation 
The first indication of peptide transporters was discovered from the studies of 
various mutant cell lines deficient in cell surface expression of MHC class I molecules, 
even though the expression levels of MHC class I heavy chain and β2m are normal Chapter 1    Introduction 
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(DeMars et al., 1985). The genes responsible for these defective phenotypes are tap1 and 
tap2 located in the MHC class II locus of human chromosome 6 (Trowsdale et al., 1991). 
Transfection of these cell lines with cDNA of TAP1 and TAP2 could restore cell surfaces 
expression of the MHC class I molecules (Attaya et al., 1992; Powis et al., 1991; Spies et 
al., 1992; Spies and DeMars, 1991). Heterologous expression of TAP1 and TAP2 in insect 
cells and yeast showed a functional peptide translocation in the absence of factors of the 
adaptive immune system (Meyer et al., 1994; Urlinger et al., 1997). 
1.3.1 Structural  organization 
TAP1 and TAP2 are localized in the ER or cis-Golgi membrane as shown by 
immunoelectron and immunofluorescence studies (Kleijmeer et al., 1992; Meyer et al., 
1994). Both proteins lack an N-terminal signal sequence for ER targeting, suggesting that 
the insertion of the proteins in the ER membrane may be promoted by an internal signal 
sequence. The functional peptide transporter is organized as a heterodimer containing 
TAP1 and TAP2 (Kelly et al., 1992; Spies et al., 1992). 
TAP1 and TAP2 belong to the ABC transporter superfamily and are so-called half-
size transporters composed of a hydrophobic transmembrane domain (TMD) followed by a 
highly conserved nucleotide-binding domain (NBD). The sequence identity within the 
NBDs is 60% whereas within the TMDs of TAP it is only 30%. As mentioned in the 
structure of ABC transporters, a 2×6 transmembrane helix model was proposed to be the 
core domain sufficient for substrate translocation. Based on hydrophobicity analysis, the 
human TAP1 and TAP2 contain 6-10 helix depending on the algorithm used. Sequence 
alignment with other ABC transporters show weak but significant similarity from TM1 
through TM6, excluding the first 175 residues for hTAP1 and 140 for hTAP2. Based on 
these knowledge, a topological model was proposed for TAP complexes as shown in Fig. 
1-5 (Abele and Tampé, 1999). Derived from such a model, the mini-TAP protein which 
only contains these 6 helices (TM 1-6) for each subunit can process full peptide transport 
activity (Koch et al., 2004). The hydrophobic N-terminal regions contain probably 
additional four and three transmembrane helices for TAP1 and TAP2, respectively (TM 
N1-N4 and TM N1-N3, N stands for N-domain as shown in Fig. 1-5), which were proven 
to be essential for interaction with tapasin (Koch et al., 2004).  Chapter 1    Introduction 
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The peptide-binding site of human TAP is contributed by the transmembrane 
domains of both subunits (Androlewicz et al., 1993; Androlewicz et al., 1994). Mapped by 
photo-crosslinking experiments, the cytosolic loops between TM4 and TM5 and a C-
terminal stretch of approximately 15 amino acids after TM6 are shown to be involved in 
peptide binding (Nijenhuis and Hammerling, 1996; Nijenhuis et al., 1996). Deletion of 
some of these amino acids in the TAP1 region resulted in loss of peptide transport (Ritz et 
al., 2001). 
 
 
1.3.2 Peptide  specificity 
The first information about substrate specificity of TAP was obtained by comparing 
the sequence of peptides transported into the ER or bound to MHC class I molecules 
(Androlewicz et al., 1993; Neefjes et al., 1993b). Peptides of 8-12 amino acids long were 
observed to be transported most efficiently, whereas van Endert et al. showed an optimal 
 
 
Figure 1-5. Membrane topology of the human TAP complex (Abele and Tampé, 1999).
The transmembrane helices are predicted from hydrophobicity plots and sequence
alignments with other ABC transporters. The unique N-terminal domains of TAP1 (N1-4)
and TAP2 (N1-3) are very hydrophobic, comprising four and three predicted transmembrane
helices, respectively (orange cylinders). Orange lines illustrate binding regions for peptides.Chapter 1    Introduction 
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length for peptide binding is 8-16 amino acids (Koopmann et al., 1996; van Endert et al., 
1994). Nevertheless, peptides of 6 or 40 amino acids in length are also transported by TAP 
albeit in considerable lower efficiency (Koopmann et al., 1996). As previously mentioned, 
the optimal length of peptides for loading to MHC class I molecules is 8-10 amino acids. 
TAP transports peptides with similar or slightly larger length suitable for MHC class I 
binding. ERAAP, ER aminopeptidase associated with antigen processing, is reported to be 
responsible for further trimming of the transported peptides in the ER (Falk and Rotzschke, 
2002; Saric et al., 2002; Serwold et al., 2002; York et al., 2002).  
In addition to the size of the peptide, its sequence also determines the efficiency of 
translocation by TAP. The recognition principle of TAP was resolved by screening 
combinatorial peptide libraries (Uebel et al., 1997). In this method, the average affinity of a 
randomized peptide mixture with one residue in common was compared with a totally 
randomized peptide library. Hence, the influence of each amino acid on the affinity for 
TAP could be determined. The first three N-terminal and the last C-terminal residues were 
found to be most critical for peptide-binding specificity (Fig. 1-6A). At the N-terminus, 
human TAP generally displays preferences for peptides with Lys, Asn and Arg in the first, 
Arg in the second, and Trp and Tyr in the third position. The C-terminal residue is 
preferred to be a hydrophobic or basic residue by human TAP. It is noteworthy that the 
peptide-binding spectrum of TAP and MHC class I molecular overlap in their C-terminal 
residue, suggesting that the binding principle of TAP and MHC class I molecule coevolved. 
Furthermore, substrate recognition by TAP is also strictly stereospecific. Introducing the D-
amino acids at two opposite terminals of peptides causes complete abrogation of transport 
(Gromme et al., 1997; Uebel et al., 1997). Acetylation or methylation of the N-terminus or 
conversion of the C-terminal carboxyl group of a peptide to an amide decreases its 
translocation efficiency considerably (Momburg et al., 1994; Schumacher et al., 1994). 
Circular peptides, which lacks of a free termini are generally not a substrate for TAP. 
Indicated by the structure of MHC class I molecule, the hydrogen bonds between the two 
termini and MHC class I molecules contribute largely to the free energy of binding. 
Therefore, TAP was expected to apply an analogous strategy for peptide binding. The 
residues in the center of the peptide have only a little or no effect on the substrate 
specificity of TAP. Interestingly, these residues are responsible for the detection of the 
MHC class I–bound peptide by the T-cell receptor. In conclusion, TAP binds peptides Chapter 1    Introduction 
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through the two termini and transports them with maximal diversity in the center of the 
peptide for T-cell recognition (Fig. 1-6B). 
 
 
1.3.3  ATP binding and hydrolysis 
ABC transporters hydrolyze ATP to provide the energy for translocation of 
substrate across the biological membrane. In addition to serve as a energy source, ATP 
appears to be also an allosteric regulator for TAP (Karttunen et al., 1999). It was found that 
nucleotides and peptides play a critical role in stabilizing the TAP heterodimer at 37°C 
(van Endert, 1999). Knittler and colleagues reported that release of the MHC class I 
molecules from a mutated TAP complex, which could not bind ATP as a result of 
 
 
Figure 1-6. Substrate recognition motif of human TAP (Abele and Tampé, 1999).
A, TAP selectivity is illustrated for positions of the peptide. Favored (upper) and
disfavored residues (lower) are given at the individual positions as elucidated using
combinatorial peptide libraries. B, A model of the substrate-binding pocket is shown in
the lower panel. Chapter 1    Introduction 
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mutations in the Walker A site, requires addition of ATP, ADP or even a non-hydrolysable 
ATP analogue (Knittler et al., 1999). The most surprising observation made in this study 
was that peptide binding was disrupted in this mutated TAP complex, indicating nucleotide 
binding plays a critical role in binding of peptide to TAP and the subsequent release of 
MHC class I molecules (Knittler et al., 1999). However, this concept is contradictory to 
previous studies on wild-type TAP, in which peptide binding to TAP was not affected by 
depletion of ATP using apyrase (Androlewicz et al., 1994; Neefjes et al., 1993b). 
Peptide transport by TAP strictly requires ATP hydrolysis, as ADP or non-
hydrolysable ATP derivatives are unable to support peptide transport (Neefjes et al., 1993b; 
Uebel et al., 1997; van Endert et al., 1994). Successful reconstitution of partially purified 
TAP into proteoliposomes has recently allowed direct measurement of the ATPase activity 
of the peptide transporter (Gorbulev et al., 2001). The Michaelis–Menten constant of ATP 
hydrolysis (300 µM) is similar to that of other ABC transporters. Moreover, peptides 
stimulate ATP hydrolysis in a manner that is proportional to their TAP affinity, 
demonstrating crosstalk between the peptide and nucleotide-binding sites. A single TAP 
complex was found to hydrolyze about a maximum of five molecules of ATP per second. 
Both NBDs seem to be essential for efficient peptide transport. It was found that the 
rat TAP chimeras containing two identical NBD possessed no peptide transport activity 
(Daumke and Knittler, 2001); whereas another group still observed a reduced but 
significant transport activity in similar constructs of human TAP (Arora et al., 2001). In 
contrast, chimeras with two switched NBDs generally retain the peptide transport ability 
(Arora et al., 2001; Daumke and Knittler, 2001). However, it is not known whether ATP 
hydrolysis by TAP1, TAP2, or both is needed for a completion of ATP hydrolysis cycle. In 
the TAP chimeras having the switched NBDs, the nucleotide binding properties of each 
individual NBD are conserved independent of the TMD linked with, indicating that NBDs 
operate as independent modules. The study also showed that the C-terminal tails of the two 
NBDs are responsible for maintaining their intrinsic property of the NBD (Bouabe and 
Knittler, 2003). 
TAP1 and TAP2 showed distinct roles in the study of peptide transport in different 
TAP mutants. Mutation of the critical lysine residue at Walker A motif of TAP2 abolishes 
the peptide transport; by contrast, complexes with the identical mutation at TAP1 showed 
low but consistent transport activity (Karttunen et al., 2001; Lapinski et al., 2001; Sauna et Chapter 1    Introduction 
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al., 2001b). Furthermore, rat TAP complexes bearing the substitution of proline-asparagine 
(GPNG) with serine-serine (GSSG) of Walker A at TAP2 almost lost the peptide transport 
ability, whereas TAP1 mutants behaved as wild type protein (Alberts et al., 2001). These 
results suggest that ATP hydrolysis at TAP1 might not be essential for the peptide 
transport. 
1.3.4 Viral  inhibitors 
Viruses have evolved several mechanisms to interfere with TAP function in order 
to evade CTL-mediated immune responses. 
The herpes simplex virus (HSV) type 1 and 2 encoding immediate early protein 
ICP47 blocks release of MHC class I molecules from the ER (Hill et al., 1994; York et al., 
1994). ICP47 inhibits binding and translocation of peptides from the cytosol into the ER 
lumen without interfering with ATP binding (Fruh et al., 1995). ICP47 from HSV type I is 
an 88 amino acid (9 kDa) cytosolic polypeptide that binds to TAP with high affinity (50 
nM) (Ahn et al., 1996; Fruh et al., 1995; Hill et al., 1994). Residues 3-34 are the minimum 
sequence which can form an active region responsible for TAP binding and subsequent 
inhibition of TAP function (Galocha et al., 1997; Neumann et al., 1997). Interaction of 
ICP47 with the TAP complex is species-specific, since murine TAP is not efficiently 
inhibited by ICP47 from human simplex virus (Ahn et al., 1996; Fruh et al., 1995). In 
aqueous solution, the active domain of ICP47 (residues 3-34) appears to be mainly 
unstructured, but in the presence of negatively charged lipid membranes, it adopts an 
ordered helix-loop-helix structure (Beinert et al., 1997; Pfander et al., 1999). However, the 
TAP-bound conformation of ICP47 remains to be established. The binding mode of ICP47 
to TAP is probably different from that of peptides, as peptides stabilize the TAP 
heterodimer, whereas ICP47 has a destabilizing effect on TAP in cross-linking studies 
(Lacaille and Androlewicz, 1998). In addition, N-acetylated peptides cannot bind to TAP 
(Neefjes et al., 1993a), whereas N-acetylation of ICP47 has no effect on TAP inhibition 
(Galocha et al., 1997).  
The human cytomegalovirus (HCMV) US6 glycoprotein also inhibits TAP-
mediated peptide loading of MHC class I molecules (Ahn et al., 1997; Hengel et al., 1997; 
Lehner et al., 1997). The open reading frame of US6 encodes a 184 amino acid (21 kDa) 
type I membrane protein composed of a leader sequence (19 aa), an ER-luminal domain Chapter 1    Introduction 
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(125 aa), a transmembrane helix (21 aa) and a short cytoplasmic tail (18 aa). The ER-
luminal domain of US6 is sufficient for ER retention and inhibition of TAP activity (Ahn 
et al., 1997; Hengel et al., 1997; Kyritsis et al., 2001). Unlike ICP47 interfering with 
peptide binding, US6 applies a different strategy to block TAP function. It interacts with 
TAP from the ER-luminal side, and inhibits ATP binding but not ADP binding to TAP in 
the cytosol (Hewitt et al., 2001; Kyritsis et al., 2001; Lehner et al., 1997). The mechanism 
of TAP inhibition by US6 is still largely unknown. It is hypothesized that US6 induces a 
conformational change in TAP and maintains that conformation, thus it prevents ATP from 
binding to TAP (Kyritsis et al., 2001). 
1.4 Objective 
 
The transport associated with antigen processing (TAP) is essential for 
translocation of peptides generated by degradation within the ubiquitin-proteasome 
pathway into the ER, where loading of MHC class I molecules occurs. Up to now, the 
principle of the substrate recognition and specificity of TAP has been established. Despite 
this, little is known about the mechanism by which the nucleotide-binding domain 
hydrolyses ATP to provide the energy for peptide translocation. Thus the goal of the 
present work is to gain insight into the mechanistic aspect of ATP hydrolysis by the 
nucleotide-binding domains of TAP.  
Firstly, the question whether both nucleotide-binding domains are involved in 
hydrolyzing ATP was addressed. Although both nucleotide-binding domains of TAP 
complex are required for peptide transport, no data has directly proven their catalytic 
functions. Clarifying this point will provide a fundamental view on the function of the two 
NBDs. An important task was to develop a method to study the ATP hydrolysis properties 
of each subunit in TAP complex respectively. Consequently, direct evidence of two 
catalytic NBDs of TAP was presented. 
Secondly, biochemical studies of TAP Walker A mutants indicated that the TAP 
subunits are functional asymmetric in the ATP hydrolysis cycle. The discrepancy in the 
conserved C-loop of the two NBDs provides the sequence basis for the asymmetry. The 
question arises: what is the role of the non-equivalent C-loops of TAP1 and TAP2 in 
inducing asymmetric function of two NBDs? The effect of the mutation in C-loops of Chapter 1    Introduction 
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TAP1 and TAP2 was analyzed to deduce the function of the two C-loops in the transport 
cycle.  
Thirdly, the knowledge how ATP binding/hydrolysis is coupled to the structure 
rearrangement of the transmembrane domain is essential for understanding the 
translocation mechanism of ABC transporters. To study this coupling process, we mutated 
the putative catalytic base to identify a low affinity peptide-binding site and its 
concomitant state of NBDs, which were proposed to occur within the ATP hydrolysis cycle 
for ABC transporters. In addition, the role of the putative catalytic base in the TAP 
complex was addressed. Chapter 2  Material 
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2. Material 
2.1 Chemicals 
 
Table 2-1. Chemical list 
Chemicals Company 
AlCl3 Sigma-Aldrich  GmbH 
5-Amino-2,3-dihydro-1,4-phthalazinedione- 
3-aminophthalhydrazide (Luminol sodium salt) 
Sigma-Aldrich GmbH 
8-Azido-[γ-
32P]ATP or 8-azido-[α-
32P]ADP  ICN 
8-Azido-biotin-ATP  Affinity labeling technology 
Acrylamid 30% (w/v)  National Diagnostics 
Adenosine-5'-diphosphate (ADP)  Fluka Chemie GmbH 
Adenosine-5'-triphosphate (ATP)  Fluka Chemie GmbH 
Apyrase Sigma-Aldrich  GmbH 
ATP-agarose (C8 or N6 linked)  Sigma-Aldrich GmbH 
BaculoGold™ Transfection Kit  BD bioscience pharmingen 
BCA-kit Pierce 
Benzonase Merck 
BeCl2 Sigma-Aldrich  GmbH 
Biobeads SM-2  New England Biolabs 
BSA Sigma-Aldrich  GmbH 
Calf intestine alkine phosphatase  Fermentas 
Chloramine T  Riedel-de Haen 
Concanavalin A-sepharose  Sigma-Aldrich GmbH 
D-(+)-desthiobiotin Sigma-Aldrich  GmbH 
β-D-decylmaltoside  Calbiochem 
DeepVent polymerase  Biolabs 
Digitonin Calbiochem 
Dimethylsulfoxide  Fluka Chemie GmbH 
4-(4,5-Diphenyl-2-imidazolyl)-benzeneboronic acid 
(DPA) 
Sigma-Aldrich GmbH 
Dowex 1 x 8 anion exchange  Sigma-Aldrich GmbH 
Enhanced ChemiLuminescence system (ECL)  Amersham Pharmacia 
Ethylendiaminetetraacid (EDTA)  Carl Roth GmbH Chapter 2  Material 
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Ex-Taq polymerase  Takara 
Fatal bovine serum  Biochrom AG 
Hexokinase Sigma-Aldrich  GmbH 
HiTrap desalting column  Amersham Pharmacia 
trans-4-Hydroxycinnamic acid (p-Coumaric acid)  Sigma-Aldrich GmbH 
Hyperfilm chemiluminescence film  Amersham Pharmacia 
Iodoacetamidoflourescein Molecular  Probes 
Igepal (NP40)  Sigma-Aldrich GmbH 
Isopropyl-ß-D-thiogalactopyranoside (IPTG)  BTS-BioTech Trade& Service GmbH 
MultiScreen plates with glass fibre filter,  
pore size 1.0 µm  
Millipore 
Megaprime DNA labeling system  Amersham Pharmacia 
Na
125I Amersham  Pharmacia 
Nucleospin plasmid kit  Machery-Nagel GmbH & Co. KG, Düren 
β-D-Octylglycoside  Calbiochem 
Penicillin/Strepmycin (100x)  PAA laboratories GmbH 
Pfu DNA polymerase  Promega 
Phoshatidylcholine Avanti  Lipids 
Phosphatidylethanolamine Avanti  Lipids 
Plasmid midi kit  Qiagen GmbH 
Pluronic F-68 (10%)  Invitrogen 
Polycarbonate filters (200 nm)  Avestin 
Polyethylenimine cellulose plates  Merck 
Ponceau Red S  Sigma-Aldrich GmbH 
Protein A (or G) agarose  Sigma-Aldrich GmbH 
Proteinase K  Sigma-Aldrich GmbH 
Pwo DNA polymerase  Roche Diagnostics 
QIAquick gel extraction kit  Qiagen GmbH 
QIAquick spin PCR purification kit  Qiagen GmbH 
Restriction enzymes  MBI fermentas  
ScCl2 Sigma-Aldrich  GmbH 
Sephadex G-50 columns  Amersham Pharmacia 
Sepharose A  Sigma-Aldrich GmbH 
SF900II medium  Invitrogen Chapter 2  Material 
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Streptactin IBA  GmbH 
Streptavidin alkine phosphatase conjugate  IBA GmbH   
Superdex 75 30/10  Amersham Pharmacia 
Superose 200 HR 11/15  Amersham Pharmacia 
Superose 6  Amersham Pharmacia 
T4 DNA ligase  MBI Fermentas 
N,N,N‘,N‘-Tetramethylethylendiamin (TEMED)  Sigma-Aldrich GmbH 
Texas Red  Molecular Probes 
Trypan blue solution (0.4%)  Sigma-Aldrich GmbH 
  
 
2.2 Oligomers 
 
Table 2-2. Primer sequences used for cloning.* 
Name Sequence 
TAP1for(BamHI)  GAG CTC GGA TCC GTG ACA ATG GC 
TAP1rev1  GGA TCG GCC CTC TAG ATG CAT G 
TAP1rev-2  TCG GCC CTC TAG ATG CAT GCT CGA GCG GCC GCC 
TAP1-Spel-f (SpeI)  CTC CTG GAC CAC TAG TAT TTC AGG TAT G 
TAP1-Cloop-f(Mut sg-
AA) 
GCT GGG AGC CAG CTG GCA GCG GGT CAG CGA CAG 
GCA 
TAP1-Cloop-r(Mut sg-
AA) 
TGC CTG TCG CTG ACC CGC TGC CAG CTG GCT CCC 
AGC 
TAP1Mut(GD)PCR1rev  CTG CCT GTC GCT GAT CCC CTG ACA GCT G 
TAP1Mut(GV)PCR1rev  CTG CCT GTC GCT GAA CCC CTG ACA GCT G 
TAP1Mut(LA)PCR1rev  CTG ACC CCC TGA CGC CTG GCT CCC AGC 
TAP1Mut(GD)PCR1for  CAG CTG TCA GGG GAT CAG CGA CAG GCA G 
TAP1Mut(GV)PCR1for  CAG CTG TCA GGG GTT CAG CGA CAG GCA G 
TAP1Mut(LA)PCR1for  GCT GGG AGC CAG GCG TCA GGG GGT CAG 
TAP1 D668Q-F  GTA CTT ATC CTG GAT CAG GCC ACC AGT GCC CTG G 
TAP1 D668N-F  GTA CTT ATC CTG GAT AAT GCC ACC AGT GCC CTG G 
TAP1 D668Q-r  CCA GGG CAC TGG TGG CCT GAT CCA GGA TAA GTA C 
TAP1 D668N-r  CCA GGG CAC TGG TGG CAT TAT CCA GGA TAA GTA C 
TAP2nXhoI-f  CAT CAT CTC GAG ATG CGG CTC CCT GCC CTG AGA 
CC Chapter 2  Material 
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TAP2XhoI-f  CAT CAT CTC GAG CAT GCG GCT CCC TGC CCT GAG 
ACC 
TAP2-Bsp1407I-f  GCG GAG AAG GTG TAC AAC ACC CGC CAT CAG 
TAP2-SphI-r*  GTA GCA TGC TCC TAG AGC TGG GCA AGC TTC 
TAP2-Sphl-r  TTT GCG CAT GCT CCT AGA GCT GGG CAA GC 
TAP2-Cloop-r(Mut aa-
SG) 
CGT TGT TTC TGT CCC CCA GAC AGC TGG CTT CCC 
TTC 
TAP2-Cloop-f(Mut aa-
SG) 
GAA GGG AAG CCA GCT GTC TGG GGG ACA GAA ACA 
ACG 
TAP2Mut(LA)pcr1-r  GTC CCG CAG CCG CCT GGC TTC CCT TCT C 
TAP2Mut(LA)PCR2-f  GGA AGC CAG GCG GCT GCG GGA CAG AAA C 
TAP2Mut(GV)pcr1-r  TGT TTC TGT ACC GCA GCC AGC TGG CTT C 
TAP2Mut(GV)pcr2-f  GCT GGC TGC GGT ACA GAA ACA ACG TC 
TAP2Mut(GD)pcr1-r  TGT TTC TGG TCC GCA GCC AGC TGG CTT C 
TAP2Mut(GD)pcr2-f  GCT GGC TGC GGA CCA GAA ACA ACG TCT G 
TAP2 E632Q-f  GGG TCC TCA TCC TGG ATC AGG CTA CTA GTG CCC 
TAG 
TAP2 E632Q-R  CTA GGG CAC TAG TAG CCT GAT CCA GGA TGA GGA 
CCC 
*The mutation sites or the restriction sites are underlined. 
 
 
Table 2-3. Primers used for verifying the recombinant Bacmid DNA 
Primers Sequence 
TAP2-Bsp1407I-f  GCG GAG AAG GTG TAC AAC ACC CGC CAT CAG
M13-f  TGT AAA ACG ACG GCC AGT 
M13-r  CAG GAA ACA GCT ATG ACC  
 
Table 2-4. Primers used for TAP1 sequencing 
Primers Sequence 
1F1   CTGCTTTGAA GCCATTAG 
1F2   CAGTGCAGTG CTGGAGTTC 
1F3 CATTGAGGCT  CTGTCG 
1F4 ACTCCCTT  ACACTTGGAG Chapter 2  Material 
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1F5 CTCCCTCAG  GGCTATGAC 
1R1 TGCGGGCAGTGCCGCTGC 
RG 4 1B  GCC ATG CGA GAG AAG CTC 
RG4 H1  ATG GCT AGC TCT AGG TGT 
RG4 H2  CTG GCT GGC TGC TTT GAA 
RG4 H3  CTC GGA GAC GCG CCG CCT 
RG4 H4  GGA GAC GGA GTT TTT CCA 
RG4 H5  AAG TCC AGC CAG GTG GCC 
RG4 H5B  AGGTGCGGGAATCTCTGGCA 
RG4 H6  TGC AGT TCA CCC AGG CTG 
RG4 H7  CTG GGA AGA GCA CAG TGG 
RG4 H8  ATG ACA CAG AGG TAG ACG 
RG4 H8B  AGG CTG GGA GCC AGC TGT CA 
RG4 II  CAC CAG CAG CTC ATG GAG 
 
 
Table 2-5. Primers used for TAP2 sequencing 
Primers Sequence 
RG11 H1  TGA CTG TCT CCC TGA G 
RG11 H2  TGG GAG GTG ATT TTG ACC 
RG11 H3  GCT CAG CAT ATC GCC TCG 
RG11 H4  GCC TTG TAC CTG CTC GTA AG 
RG11 H5  GAC AGG CCT GTG CTC AAG GG 
RG11  I  CCC TGA AGC AGC CAC AGT 
RG11 IB  GGC TGG GGG AGC ACG TGA GG 
RG11 II  AGG CTG CAG ACA GTT CAG 
RG11 IIB  GAC TTC ATC CAG GAA ATG GA 
RG11 R1  CTT CTC CCC TAC ATC TGT 
RG11 R2  TCA CCT CAC CAG GAC GTA 
RG11 R3  ATC TGC TGC AGC CCA CAG CT 
RG11 R4  CAT GTG CAG CAG AGA AAG  GA 
SeqTAP2-f1  CCC CAG CCA GAG TCG CTT C 
SeqTAP2-f3  GTT TTG GGG C CG AGG AGC 
SeqTAP2-f4  TCC CAA TCG CCC TGA CAG Chapter 2  Material 
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SeqTAP2-f5  GAA GCC AGC TGG CTG CGG 
SeqTAP2-r1  CCC TGG AGA GCT TCA GCA 
 
 
2.3 Peptides 
 
Table 2-6. Peptide used in this work 
Peptides  Sequence 
C4F  RRYCKSTEL (Cysteine labeled with fluoresein) 
R9LQK RRYQKSTEL 
D-R9LQK D-RRYQKSTEL 
R9NST RRYQNSTEL 
E9D EPGNTWDED 
ICP47 (2-34)  SWALEMADTFLDTMRVGPRTYADVRDEINKRGR 
 
 
2.4 Antibodies 
 
Table 2-7. Antibody list 
Antibody Type  Protein  Recognition  site 
148.3   Monoclonal  TAP1  CYWAMVQAPADAPE 
435.3 Monoclonal  TAP2 NBD 
429.3 Monoclonal  TAP2 NBD 
1P1 Polyclonal  TAP1  GRLTDWILQDGSA 
1P2 Polyclonal  TAP1  ETEFFQQNQTGNIMSR 
1P3 Polyclonal  TAP1  TVRSFANEEGEAQKFR 
1P4 Polyclonal  TAP1  SEKIFEYLDRTPR 
2P1 Polyclonal  TAP2  RVIDILGGDFD 
2P2 Polyclonal  TAP2  RIREQLFSSLL 
2P3 Polyclonal  TAP2  EAVGGLQTVRSFGAEE 
2P4 Polyclonal  TAP2  VGAAEKVFSYMDRQPN Chapter 3  Methods 
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3. Methods 
3.1 Molecular  cloning 
3.1.1  E. coli culturing 
E. coli DH5α cells were grown in LB-medium (10 g trypton, 5 g yeast extract, 10 g 
NaCl per liter) at 37°C. If not indicated, 100 µg/ml ampicillin (final concentration) were 
added after autoclaving. E. coli DH10Bac was grown in LB-medium containing 50 µg/ml 
kanamycin and 10 µg/ml tetracycline. After transformation with pFastBacDual, 7 µg/ml 
gentamicin was added into the agar plates for selection. 
3.1.2  Competent E. coli cells (calcium-mediated) 
An overnight culture of E. coli DH5α cells was diluted 1:50 in 100 ml LB-medium 
and grown at 37°C to an OD600 of 0.5. The culture was cooled down and the cells were 
harvested at 1,000 g for 10 min at 4°C. The cell pellet was carefully resuspended in 10ml 
sterile, ice-cold 0.1 M CaCl2 and incubated on ice for 90 min. After centrifugation the 
pellet was resuspended in 2 ml ice-cold 0.1 M CaCl2 and 400 µl 87% glycerol. Cell 
aliquots of 100 µl were frozen in liquid nitrogen and stored at –80°C. To make E. coli 
DH10Bac competent cell, the same procedure was applied except for LB-medium 
containing 50 µg/ml kanamycin and 10 µg/ml tetracycline. 
3.1.3  Transformation of competent E. coli 
Competent E. coli cells were strictly thawed on ice for 10 min. Plasmid DNA (10ng 
to 1 µg) was dissolved in 10 µl water, mixed with 100 µl of competent cells and incubated 
on ice for 30 min. The suspension was transferred to 42°C for 90 sec (heat shock). The 
cells were regenerated in 1 ml LB-medium for 1 h at 37°C with vigorous shaking. The cell 
suspension was centrifuged (1,000 g, 10 min, 25°C) and plated on pre-warmed (37°C) LB-
agar plates supplemented with the appropriate antibiotics and incubated overnight at 37°C. 
3.1.4  DNA preparation, processing and electrophoresis 
To obtain highly purified plasmids for sequencing, DNA was isolated by MN Mini 
kit (MACHEREY-NAGEL GmbH & Co. KG, Germany). For restriction analysis, the 
plasmids were prepared by alkaline lysis method: cell pellets from 3 ml overnight culture 
were suspended in 0.3 ml 15 mM Tris-HCl (pH 8.0), 10 mM EDTA, 100 µg/ml RNase A, Chapter 3  Methods 
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followed by gently mixing with 0.3 ml 0.2 M NaOH, 1% SDS for 5 min. After that, 0.3 ml 
of 3 M potassium acetate (pH 5.5) was slowly added to the mixture. Samples were 
incubated on ice for 4 min and then centrifuged at 14,000 g for at least 10 min. The 
supernatant was mixed with 0.8 ml isopropanol and incubated on ice for a minimum of 5 
min. Samples were then centrifuged at 14,000 g for 15 min. After removing the 
supernatant, pellets were washed once with 70% ethanol and dried by air. Finally, DNA 
pellets were redissolved in 50 µL 5 mM Tris, pH 8.5, which was ready for restriction 
analysis or cloning. 
Restriction enzyme digestion was performed in a DNA to enzyme ratio of 1 µg to 
10 units under conditions (temperature and buffer) as suggested by the manufacturer. 
Before electrophoresis, DNA samples were mixed with loading buffer (10 fold: 40% 
sucrose (w/v), 0.25% bromphenol blue, xylenecyanol in TE-buffer). DNA fragments were 
analyzed in 1% agarose gels in TAE-buffer (40 mM Tris-acetate pH 8.0, 1 mM EDTA) 
and  stained with ethidium bromide. DNA fragments were extracted from gel using 
QIAGEX extraction kit (Qiagen GmbH, Germany).  
To reduce religation of vector with blunt ends, dephosphorylation was performed. 
Routinely, 1-2 µg DNA in a total volume of 50 µl was incubated with 1 unit phosphatase 
(calf intestine) in 1x manufacturer’s reaction buffer for 1 h at 37°C. The enzyme was heat 
inactivated at 72°C for 10 min.  
Ligation was performed by incubating vector DNA with a 3-10 excess of insert 
DNA with T4-DNA ligase in 1x manufacturer’s reaction buffer overnight at 16°C. The 
total reaction volume of ligation reaction was kept to 20 µL. Before transformation, the 
sample was incubated at 60°C for 10 min to inactivate T4-DNA ligase. 
PCR (Polymerase Chain Reaction) was used to amplify insert DNA using 10 ng 
plasmid DNA as template. For PCR of high fidelity, Pwo-polymerase (MBI Fermentas 
GmbH, Germany) or DeepVent (New England Biolabs GmbH, Germany) were used 
according to manufacturer’s instructions.  
Clones were checked via restriction analysis. Positive clones were verified by DNA 
sequencing (Scientific Research & Development GmbH, Germany). 
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3.1.5  Plasmids construction for generation of baculovirus 
The plasmids construction can be divided into three steps (Fig. 3-1): 
In the first step, tap1 and tap2 wild type cDNA were inserted into pFastBacDual 
separately. TAP1 was amplified by PCR with the primers (TAP1for and TAP1rev2) taking 
p46-TAP1 (from Dr. Seliger, Mainz) as template. The PCR product containing BamHI and 
NotI sites was cloned into the pFastBacDual vector; For TAP2 cloning, primers 
TAP2nXhoI-f and TAP2-SphI-r and template p46-TAP2 (from Dr. Seliger, Mainz) were 
used to form pFastBacDual-TAP2. In addition, TAP2 was also inserted into vector 
pSL1180 using the same restriction sites. 
In the second step, mutations were introduced into pFastBacDual-TAP1 and 
pFastBacDual-TAP2. For generation of TAP C-loop single mutants, three-step overlapping 
PCR was carried out for the full tap gene (Fig. 3-2a). Primer pair used for TAP1 
amplification was TAP1for and TAP1rev-2; for TAP2 was TAP2nXhoI-f and TAP2-Sphl-
r. Mutagenesis PCR products were exchanged with their wild type fragments in 
pFastBacDual-TAP1 and pFastBacDul-TAP2. However, extra mutations introduced by 
PCR became a general problem. Therefore, shorter templates were applied during 
construction of C-loop exchange mutants, which are between SpeI and NotI restriction 
sites of tap1 gene and Bsp1407 and SphI sites of tap2 gene. Mutagenesis PCR products 
were cloned into pFastBacDual-TAP1 and pSL1180-TAP2 by substituting the wild type 
fragments. 
For generation of TAP1 D668Q/N and TAP2 E653Q mutants, quick exchange 
mutagenesis kit (Stratagene, USA) was used as manufacture’s instruction with vectors 
pFastBacDual-TAP1 and pSL1180-TAP2 as template (Fig.3-2B). After introducing the 
mutations, the fragments between SpeI and NotI sites of TAP1 as well as Bsp1407 and 
SphI sites of TAP2 were cut out and exchanged with their wide type in pFastBacDual-
TAP1 and pSL1180-TAP2. 
In the third step, TAP2 mutant gene fragments were cut from the pSL1180-TAP2 or 
pBastBacDual-TAP2 using XhoI and SphI and were subsequently ligated into 
pFastBacDual-TAP1, ending up with pFastBacDual-TAP1/2 bearing double genes.  
 Chapter 3  Methods 
  27
 
 
 Chapter 3  Methods 
  28
 
 
3.1.6  Transposition in DH10Bac 
100 µL of competent DH10Bac cells were thawed on ice. 1 µL of DNA from mini-
prep (usually 0.5 µg/µL) was added to the cells and the mixture was incubated on ice for 
30 min. Then, cells were heat-shocked at 42°C for 45 seconds and immediately transferred 
to 4°C for 2 min. 1 ml SOC media was added and cells were subsequently incubated at 
37°C for 4 hours. Cells were then spinned down and diluted serially with SOC medium 
(20g tryptone, 5 g yeast extract, 0.5 g NaCl, 0.186 g KCl in 970 ml H2O; after autoclaving, 
 
 
Figure 3-2. Introduction of mutation by PCR. A, three steps overlapping mutagenesis
PCR. The gene was subdivided into two parts and amplified by PCR1 and PCR2
respectively. Full-length gene bearing the site-direct mutation was re-synthesized by
PCR3. DNA Polymerases creating an ‘a’-overhang should be avoided for this method. B,
quick change mutagenesis. step I: a thermal cycling step to achieve multiple rounds of
mutant strand  synthesis; step II: digestion of parental DNA via Dpn I; step III:
transformation of ssDNA into competent cells. 
Figure 3-1. Constrution of TAP variants expression vector (previsous page). The
construction of TAP expression vector was followed by three steps: I, cloning of TAP1 into
pFastBacDual via BamHI and NotI, resulting pFastBacDual-TAP1; Cloning of TAP2 into
pFastBacDual or pSL1180 via XhoI and SphI, resulting pFastBacDual-TAP2 or pSL1180-
TAP2. II, based on these vectors, mutagenesis was carried out by PCR (shown by Fig. 3-2). III,
TAP2 fragment was cut out and insert into pFastBacDual-TAP1, ending up with pFastBacDual-
TAP1/2 Chapter 3  Methods 
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5ml sterile solution of 2 M MgCl2 and 20 ml 1 M glucose were added just before use) to 
10
–1, 10
-2 and 10
-3. 100 µL mixture of each dilution was plated onto LB agar plates 
containing 50 µg/ml kanamycin, 7 µg/ml gentamicin, 10 µg/ml tetracycline, 100 µg/ml 
Bluo-Gal and 40 µg/ml IPTG. Plates were incubated at 37°C for at least 36 hours for 
development of blue-white colonies. The whites clonies were amplified to isolate the 
recombinant Bacmids for transfection of insect cells. 
3.2 Cell  culture 
3.2.1  Culture of Raji cells 
Human Burkitt lymphoma cells (Raji cells) were propagated in roller bottles at 
37°C and 5% CO2 in RPMI medium 1640 supplemented with 10% FCS, 1 mM sodium 
pyruvate, and 40 units/ml each of penicillin and streptomycin. Cell density of the culture 
was generally maintained at 3~9×10
6 cells/ml. 
3.2.2  Monolayer culture of insect Sf9 cells 
Spodoptera frugiperda (Sf9) monolayer culture was kept in SF900 II medium 
(including 10 units/ml Penicilin, 0.1 mg/ml Streptomycin, 0.2% pluromic acid and 5% fetal 
calf serum). Before passage, medium and floating cells from a confluent monolayer were 
discarded by aspiration. 10 ml of prewarmed SF900 II medium was added to 75 cm
2 flask. 
Cells were then detached from the surface by tapping the flask. 2.5 ml of the cell mixture 
was diluted into a new flask in 10 ml medium and incubated at 27 °C. 
3.2.3  Shaker culture of insect Sf9 cells 
Sf9 cells were maintained in SF900 II medium for monolayer culture with or 
without serum. The culture flask was incubated at 27°C in less than 1/4 of the total flask 
volume until it reaches a cell density of 2×10
6 cells/ml. Then cells were diluted to 0.4×10
6 
cells/ml with fresh medium. The cultures must be avoided to reach stationary phase at any 
time (for cells in Sf-900 II SFM this is a density of 5×10
6 cells/ml). 
3.2.4  Transfection of Sf9 cells 
2×10
6 Sf9 cells were seeded onto a 60 mm tissue culture plate. Initial cell density 
should be 50-70% confluent. Cells were incubated at 27°C for 1 hour to allow them to 
attach firmly onto the plate. Then the culture medium was removed and 1 ml of Chapter 3  Methods 
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transfection buffer A (BaculoGold
TM) was added to the plate. All areas of the plate should 
be covered by this buffer. 5 µg bacmid DNA from mini-prep was mixed with 1 ml 
transfection buffer B. Subsequently the mixture was added to the plates drop by drop. After 
every two or three drops, the plate should be gently rotated to facilitate the mixing of 
buffer B with buffer A. Following incubation of the plate at 27°C for 4 hours, the 
transfection solution was removed and 3 ml of fresh SF900 II medium was added to the 
cells. The plate was incubated at 27°C for 5-7 days before new recombinant virus (P1 
stock) can be harvested. 
3.2.5  Amplification of virus 
3 ml P1 virus stock harvested from transfection generally has a titre of 1 x 10
7 
pfu/ml. Virus were amplified two times before going for infection of cells in a large scale. 
10 ml P2 was obtained by infecting 1.2 x 10
6 cells monolayer in 75 cm
2 flask for 5 days 
with 1 ml P1 stock; after that, 25 ml P3 can be harvested from infection of 3 x 10
7 cells 
with 3 ml in 175 cm
2 flask for 5 days. All media used for the amplification of virus 
contained FCS. 
3.2.6  Infection of Sf9 cells for protein production 
450 ml shaker culture of Sf9 cells were grown at 27°C in serum free medium in a 
Fernbach flask to a density of 2 x 10
6 cells/ ml. 25 ml of virus stock P3 was added and the 
culture was continually incubated until 30% cell death rate was achieved. Subsequently 
cells were harvested by centrifugation at 200 g for 5 min. Cell pellets were washed with 20 
ml PBS once and kept frozen at –20°C. 
3.2.7  Determination of virus titre by plaque assay 
Sf9 cells (1 x 10
6 cells) was seeded into 35 mm petri dishes and incubated at room 
temperature for 2 hours. Virus stock was diluted in serial from 10
-1, 10
-2 to 10
-7. After 
removal of the medium from the culture, 100 µl virus dilution was added to the dishes, 
which were incubated at room temperature outside the hood for 1 hour with gentle 
agitation every 15 min. During incubation, the agarose solution was prepared by 
combining 8 ml medium with 4 ml 3% low melting agarose (plus 120 µL X-gal 25 mg/ml 
in DMF). After that, the viral solution was removed and 2 ml of 1% agarose solution was 
added onto each dish. When the agarose solidified, 1 ml medium was overlaid on it. The Chapter 3  Methods 
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dishes were kept at 27°C for 3-4 days and then stained with 1 ml Neutral Red/PBS solution 
(1 vol of 0.4% neutral red to 19 vol of PBS). After incubation at 27°C in the dark for 2 
hours, the liquid was removed. Incubation of inverted dishes overnight resulted in several 
white plaques in dark red background. Each plaque is generated by infection of Sf9 cells 
with an individual baculovirus particle, therefore the total amount of the virus can be 
determined. 
3.3  General biochemical methods 
3.3.1  SDS-PAGE (mini gel) 
The stacking gel buffer is composed of 0.5 M Tris-HCl, pH 6.8 and 0.4% SDS. The 
running gel buffer contains 1.5 M Tris-HCl, pH 8.8 and 0.4% SDS. The acrylamide 
solution consists of 30% acrylamide and 0.8% N,N´-methylenebisacrylamide. Stock 
aliquots of 10% ammonium peroxodisulphate (APS) are prepared in water and stored 
 at -20°C. 
Before electrophoresis the proteins were denatured in 3x sample buffer (150 mM 
Tris pH 6.8, 6% SDS, 30% glycerol, 0.3% bromphenolblue and freshly added 40 mM 
DTT). Soluble proteins were incubated for 5 min at 95°C and membrane proteins were 
incubated for 15 min at 65°C. The SDS electrophoresis was performed at 120 V for 1-1.5 
hour in running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS, pH ~8.3). 
 
Table 3-1. Composition of stacking and running gel according to Laemmli (Laemmli, 1970) 
  Stacking gel  Running gel 
 5%  7.5%  10%  12% 
Acrylamide  6.8 ml  18 ml  24 ml  29 ml 
Stacking gel buffer  5 ml  -  -  - 
Running gel buffer  -  18 ml  18 ml  18 ml 
H20  28 ml  36 ml  30 ml  25 ml 
APS  320 µl  470 µl  470 µl  470 µl 
TEMED  32 µl  40 µl  40 µl  40 µl 
 
3.3.2  SDS-PAGE (maxi gel) 
To resolve TAP1 and TAP2 subunits with SDS-PAGE, a big gel electrophoresis 
system (gel size: L×W=30×20 cm) was used. The composition of gel is shown in table 3-2. 
The stacking gel buffer is composed of 0.5 M Tris-HCl, pH 6.8; the running gel buffer Chapter 3  Methods 
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contains 2 M Tris-HCl, pH 8.8; the acrylamide solution was the same as for the mini gel. 
Sucrose solution was 60%. The SDS electrophoresis was performed at constant 20 mA for 
24 h in running buffer (50 mM Tris, 384 mM glycine, 0.1% SDS, pH ~8.6). 
 
Table 3-2. Composition of stacking and running gel according to Laemmli (Laemmli, 1970) 
  Stacking gel  Running gel 
 5%  11% 
Acrylamide  5 ml  29.3 ml 
Stacking gel buffer  4ml  - 
Running gel buffer  -  16 ml 
Sucrose (60%)  7 ml  - 
H20  14 ml  33 ml 
SDS (10%)  300 µL  800 µL 
APS  150 µL  240 µL 
TEMED  15 µL  40 µL 
 
3.3.3 Western  blotting 
To transfer proteins from the gel onto nitrocellulose, a blotting sandwich was 
prepared with the following layers: 1) filter paper soaked in transfer buffer (25 mM Tris, 
192 mM glycine, 20% methanol, pH 8.2), 2) gel, 3) membrane soaked in transfer buffer (in 
the case of PVDF membrane, it should be soaked in methanol for 1 min previously), 4) 
filter paper soaked in transfer buffer. The sandwich was set onto a semidry blotting 
apparatus (Bio-Rad Laboratories GmbH, Germany) with the nitrocellulose/PVDF 
membrane facing the anode. The electroblotting was performed at constant current (100 
mA per mini gel) for 90 min. To determine the efficiency of the transfer process, the 
membrane was stained with Ponceau Red (0.1% Ponceau Red S, 5% acetic acid) for 5 min, 
and washed with water until defined bands were visible. For immunodetection the 
membrane was blocked with blocking buffer (TBS-T: 10 mM Tris-HCl pH 8.0, 150 mM 
NaCl, 0.1% (v/v) Triton X-100, including 7% (w/v) skim milk powder and 0.1% (w/v) 
NaN3) for at least 30 min at RT or overnight at 4°C. The membrane was incubated at RT 
for 1 h with the primary antibody diluted in TBS-T buffer. After 3 times washing with 
TBS-T for 10 min, the membrane was incubated with horseradish peroxidase conjugated 
second antibodies (1:10,000) for 1 hour. Subsequently, the membrane was washed again 3 
times and incubated with 10 ml ECL1 buffer (2.5 mM luminol sodium salt, 0.4 mM Chapter 3  Methods 
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coumaric acid in 100 mM Tris, pH 8.5) for 5 min, followed by 10 ml ECL2 buffer (6.4 µL 
30% H2O2 in 10 ml 100 mM Tris, pH 8.5) for 30 sec. The chemiluminescent signal was 
detected by a LumiImager. 
3.3.4  Stripping of immunoblots 
To develop the same western blot with different antibodies, membranes were 
stripped with stripping buffer (150 mM glycine, pH 3.0) for 1 hour at room temperature 
and washed afterwards with TBS, 0.1% Triton X-100 before extensive blocking (at least 1 
h) and incubation with the next antibody. For a harsher method, the membrane was 
incubated in stripping buffer containing 50 mM Tris, pH 6.7, 100 mM mercaptoethenal, 
2% SDS (w/v) for 20 min at 50°C before the washing step.  
3.4  Biochemical assays for TAP 
3.4.1  Preparation of microsomes 
Sf9 cell pellets (10
9 cells from 500 ml culture) were thawed and resuspended in 3 
volume of cavitation buffer (50 mM Tris, pH 7.5, 250 mM sucrose, 25 mM K2Ac  
and 4 mM MgAc) plus 1 mM DTT and protease inhibitors (50 µg/ml AEBSF 
hydrochloride, 1 µg/ml aprotinin, 10 µg/ml leupeptin, 5 µg/ml pepstatin A and 150 µg/ml 
benzamidin). After incubation on ice for 30 min, cells were then homogenized by a glass 
douncer and centrifuged at 200 g for 2 min followed by 700 g for 7 min. The resulting 
supernatants were loaded on the top of the sucrose gradient, which contained 5 ml 2.7 M 
sucrose buffer (50 mM Tris, pH 7.5, 2.7 mM sucrose, 150 mM K2Ac, 5 mM MgAc and 0.5 
mM CaAc), overlaid with 6 ml 1.8 M sucrose buffer and 5 ml 0.4 M sucrose buffer. The 
sucrose gradient was centrifuged at 103,000 g overnight in a SW-28 rotor. The microsomes 
were harvested from the 1.8 M / 0.4 M sucrose interphase and diluted with 2 volumes of 
PBS, pH 7.0, 1 mM DTT. The suspension was centrifuged at 160,000 g in Ti50 rotor for 
20 min. The pellet was resuspended in 5 ml PBS, pH 7.0, 1 mM DTT, and aliquots were 
frozen in liquid nitrogen and stored at –80°C. Microsomes from Raji cells were prepared 
following the same procedure, except that the cavitation buffer contains 10 mM HEPEs, 
pH 7.4, 5mM MgCl2 and 0.5 mM CaCl2. Chapter 3  Methods 
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3.4.2  Peptide labeling with Na
125I 
Peptides were iodinated using the chloramine T-method (Hunter and Greenwood, 
1964). Chloramine T solution (1 mg/ml) and sodium bisulfite (0.17 mg/ml) were freshly 
prepared in PBS, pH 7.0. The reaction was routinely performed with 1.5 nmol peptide in a 
total volume of 50 µl and 1 µl (100 µCi) Na
125I. The reaction was started by addition of 
10µl chloramine T. After 5 min incubation at RT the reaction was stopped by addition of 
120µl Na2S2O5 (sodiumbisulfite). Free iodine was removed by anion exchange 
chromatography using Dowex 1 x 8 material. Dowex (10 mg) was equilibrated in PBS, 
pH7.0 containing 0.2% dialyzed BSA and was washed 2 times with PBS buffer without 
BSA. The Dowex suspension (220 µl) was added to the radiolabeled reaction mix, 
vortexed and incubated for 5 min at RT. The suspension was applied to an empty spin 
column and centrifuged for 2 min at full speed. The flow-through contained the 
radiolabeled peptide in a concentration of 3.75 µM. 
3.4.3  Peptide labeling with fluorescein 
Iodoacetamidofluorescein stock solution was prepared at 50 mM in DMF. Peptide 
RRYCKSTEL was dissolved in PBS, pH 6.5, 20% DMF to a concentration of 5 mM. 1.2 
molar excess of iodoacetamidofluorescein was immediately added to the peptides and the 
reaction took place in the dark for 2 hours. The reaction was quenched by adding DTT. 
Mixture was loaded onto a C18 column (Kontronsorb, C18) equilibriated with 0.1% 
trifluoroacetic acid solution at the KONTRON HPLC system. After that, free fluorescein 
was separated from peptides with an acetone gradient running from 0-100% within 50 min 
at a flow rate of 2 ml/min. The absorption at 490 nm was monitored to localize the 
fluorescein and peptides. The peak containing fluorescein-labeled peptides was pooled and 
lyophilized to evaporate all solvents. Peptides were re-dissolved in milliQ water, and the 
peptide concentration was determined by measuring absorption at 492 nm in Tricine 
buffer, pH 9.0 (molar extinction coefficients: 75000 cm
-1 M
-1). The purity of the 
fluorescein-labeled peptides was identified by MS spectrometry. 
3.4.4  Peptide binding assay (centrifuge) 
Peptide binding to TAP in microsomes was analyzed in AP buffer (PBS, 5 mM 
MgCl2, pH 7.0). Microsomes (100 µg proteins) were mixed with 
125I-labeled peptide 
R9LQK (for detailed concentration see figure legend) in a volume of 150 µl. The control Chapter 3  Methods 
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sample contained 400-fold excess of unlabeled peptide in the mixture. After 15 min of 
incubation on ice, 1 ml of AP buffer was added and microsomes were centrifuged at 
20,000 g for 8 min. After washing with 500 µl of AP buffer, the radioactivity associated 
with microsomes was quantified by γ-counting.  
3.4.5  Peptide binding assay (filter) 
The filtration assay was performed using a multiple filtration manifold (Multiscreen 
Assay System, Millipore) that is capable of handling 96 samples in parallel. The binding 
reaction took place in multi-well plates in which microsomes (15 µg protein) were mixed 
with radiolabeled peptide R9LQK at indicated concentration in an AP buffer in a final 
volume of 50 µL. After incubation on ice for 15 min, the mixture was transferred onto a 
multiscreen filter (MultiScreen Plates with glass fibre filter, pore size 1.0 µm, Millipore), 
which was preincubated with 100 µL 0.3% polyethyimine, followed by 100 µL of 0.2% 
dialysed BSA. Unbound peptide was removed by washing with 150 µl ice-cold AP buffer 
twice. The filters were air-dried, and radioactivity was quantified by γ-counting. The 
amount of bound, labeled peptides were corrected for unspecific binding, which was 
determined in the presence of a 400-fold molar excess of unlabeled peptide R9LQK. To 
determine the peptide dissociation constant, the data were fitted with Langmuir (1:1) 
binding equation: 
B = max B ×
C K
C
d +
 
3.4.6  Peptide binding kinetics 
Fluorescein-labeled peptides (C4F) were preincubated in 1 ml AP buffer at 4°C or 
27°C. After reaching a stable fuorescence emission signal, microsomes containing TAP 
were injected into the cuvette. Prior to use, microsomes were depleted of ATP by 
pretreatment with 1 unit apyrase (Sigma, Germany) for 10 min. The total protein and TAP 
concentration were around 100 µg/ml and 10 nM, respectively. When binding reached 
equilibrium as indicated by a stable fluorescent emission signal, a 400-fold molar excess of 
non-labeled peptide (RRYQKSTEL) was added to induce the dissociation of the peptide. 
The fluorephore was excited at a wavelength of 470 nm and the emission signal at 515 nm 
was recorded using a FLUOLOG-3 spectrometer (Instruments S.A., France) equipped with 
a microstirring device. The time-dependent changes in the fluorescence signal were fitted Chapter 3  Methods 
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by a monoexponential function yielding the observed association and dissociation rate 
constants, kobs and kdis: 
F=F0+ max F ∇× exp(-kt) 
Here the F0 is the fluorescence signal at the zero time point, the  max F ∇  is the change of the 
fluorescence at equilibrium comparing to the starting point (F0). 
 
3.4.7  Determination of TAP concentration 
The amount of TAP in microsomes was considered to be equal to their active 
peptide-binding sites under saturation condition assuming one peptide-binding site per 
TAP complex. Microsomes (15 µg proteins) were incubated with 1µM peptides C4F 
(RRYC(Fluo)KSTEL) or radiolabeled R9LQK on ice for 15 min in 50 µl AP buffer. The 
mixture was loaded on to the filter plates, which were then washed with AP buffer three 
times (details see 3.4.5). In the case of using radiolabeled peptides, the radioactivity of 
filter plates was directly measured. In parallel, the radioactivity of 1 µl peptides (cpm/µl) 
was measured and the specific radioactivity of this peptide (cpm/mol) can be calculated. 
After counting the retained radioactivity of the filter plates, the total amount of the peptides 
(peptide-binding sites) was determined. For fluorescein-labled peptides (C4F), 300 µl PBS, 
1% SDS, pH 7.5 was added to the filter plate to solubilize the microsomes as well as the 
peptides. Filter plate was incubated at room temperature for at least 15 min. Subsequently, 
the fluorescence emission of the solution was measured in the multi-well plate at 520 nm 
with the excitation wavelength at 470 nm using FluoroStar fluorometer (BMG 
Labtechnologies, GmbH, Germany). The C4F peptide was diluted in PBS, 1% SDS,   
pH 7.5 to a series of defined concentration (0, 10, 20, 40, 80 and 160 nM), which were 
served as the standard.  
3.4.8 Peptide  transport 
Microsomes (250 µg of proteins) were incubated with 1 µM I
125-labeled 
RRYQNSTEL, 3 mM ATP, or ADP in 50 µl of AP buffer for 2 min at 32°C. The reaction 
was stopped by adding 500 µl of ice-cold AP buffer supplemented with 10 mM EDTA. 
After centrifugation, the pellets were solubilized in 900 µl of lysis buffer (20 mM Tris, 150 
mM NaCl, 5 mM MgCl2, 1% Igepal, pH 7.5) by incubation for 15 min on ice. The Chapter 3  Methods 
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insoluble material was removed by centrifugation, and the supernatant was incubated with 
60 µl of concanavalin A (ConA)-Sepharose (50%, v/v) for 1 hour. After three washing 
steps, the radioactivity associated with ConA-Sepharose was quantified by γ-counting. 
3.4.9  Photocrosslinking of TAP  
Microsomes were suspended in 25 µl of photocrosslinking buffer (20 mM HEPES, 
140 mM NaCl, 0.1 mM EGTA, 5 mM NaN3, 1 mM Ouabain, 2 mM Mg
2+, 15% glycerol, 
pH 7.5) containing 1 µM 8-azido-[α-
32P]ATP. After 5-min incubation at the indicated 
temperature, samples were irradiated with UV light for 5 min on ice. 500 µl of ice-cold IP 
lysis buffer (20 mM Tris, 150 mM NaCl, 1% Igepal, pH 7.5) was added. Subsequently 
samples were immunoprecipitated (see 3.4.11) and analysed by SDS-PAGE (11%). Gels 
were dried and exposed to Kodak BIOMAX
TM MS films (Kodak GmbH, Germany) with 
an intensifying screen at -80°C. 
3.4.10 Trapping of the TAP complex by ATPase inhibitors 
Microsomes were incubated in 25 µl of AP buffer containing 2 µM 8-azido-[α-
32P]ATP and 0.5 mM ATPase inhibitors (orthovanadate, BeFx, AlFx, or ScFx) in the 
presence or absence of peptides for 15 min at 27°C. In this assay, all metal fluorides were 
prepared by mixing metal chloride and sodium fluoride in a molar ratio of 1 to 100. The 
reaction was stopped by addition of 1 ml of ice-cold washing buffer (AP containing 10 
mM ATP and 0.5 mM ATPase inhibitors). Samples were incubated for 15 min on ice. 
After centrifugation at 20,000 g for 15 min, pellets were resuspended in 50 µl of washing 
buffer. Finally, samples were irradiated with UV light for 5 min and then subjected to 
immunoprecipitation (see 3.4.11). 
3.4.11 Immunoprecipitation 
After photolabeling, TAP was immunoprecipitated either as a complex or as 
disassembled TAP1 and TAP2 subunits. These two methods differ in the solubilization 
procedure. In the former case, microsomes were solubilized in 0.9 ml of IP lysis buffer (50 
mM Tris, 140 mM NaCl, 1% NP-40, pH 7.5) for 15 min on ice. In the latter case, 
microsomes were solubilized in 200 µl of IP lysis buffer for 15 min on ice. To disassemble 
the TAP complex, SDS was added to a final concentration of 0.5%, and incubation was 
continued for 15 min at 37°C. Finally, 700 µl of ice-cold IP lysis buffer was added. In both Chapter 3  Methods 
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methods, samples were centrifuged at 20,000 g for 8 min to remove insoluble material after 
solubilization. Antibodies (routinely 10 µl) were added to the supernatant and incubated 
for 2 h on ice. 50 µl of 50% (v/v) protein A/G (for monoclone/polyclonal antibody)-
agarose Fast Flow (Sigma) were added, and incubation was continued for 2 h at 4°C. After 
washing three times with 1 ml of ice-cold IP washing buffer (20 mM Tris, 150 mM NaCl, 
0.1% Igepal, pH 7.5), proteins were eluted with SDS sample buffer and applied to SDS-
PAGE (11%). Antibodies used were monoclonal antibody 148.3 (anti-TAP1), rabbit 
antiserum 1p2 (anti-TAP1), and 2p4 (anti-TAP2). The BeFx-trapped TAP complex was 
immunoprecipitated by a combination of polyclonal 1p2 and 2p4. Chapter 4  Results 
  39
4. Results 
4.1  Two catalytically active NBDs of TAP 
4.1.1 Introduction 
Peptide translocation is strictly dependent on ATP hydrolysis (Neefjes et al., 1993b; 
Uebel et al., 1997; van Endert et al., 1994). Several groups have most recently addressed 
the function of the two NBDs in the peptide transport process (van Endert et al., 2002). 
Exchanging the highly conserved, catalytic active lysine residue of the Walker A site 
impairs the transport activity strongly. Interestingly, although mutations of this residue in 
TAP2 fully interrupt peptide transport, TAP1 mutants still show low transport activity, 
suggesting distinct functions of both subunits during peptide transport (Karttunen et al., 
2001; Lapinski et al., 2001; Saveanu et al., 2001). A functional non-equivalence of the two 
NBDs has also been reported in studies exchanging the NBDs within the TAP complex. 
The chimera with switched NBDs has substantial higher transport activity than chimeras 
with two identical NBDs, indicating that two different NBDs are important for TAP 
function (Arora et al., 2001; Daumke and Knittler, 2001). However, so far it is not clear 
whether both TAP subunits catalyze ATP hydrolysis. This question could neither be 
answered by measuring ATPase activity of TAP, nor could mutagenesis studies clarify this 
point directly.  
In this chapter, the ATP hydrolysis properties of the two TAP subunits were studied 
for the first time by photolabeling with 8-azido-[α-
32P]ATP combined with BeFx trapping. 
The peptide and ATP binding of TAP complexes in the BeFx-trapped state were also 
addressed.  
4.1.2  8-Azido-ATP energizes peptide transport as efficiently as ATP  
8-Azido-ATP has been used to study the characteristics of binding and/or 
hydrolysis of ABC transporters such as P-gp, CFTR, and sulfonylurea receptor 1 (SUR1) 
(Hrycyna et al., 1998; Szabo et al., 1998; Takada et al., 1998; Ueda et al., 1999; Urbatsch 
et al., 1995a). Before using 8-azido-ATP to probe ATP hydrolysis by TAP, we determined 
whether this ATP-analog drives peptide transport. Therefore, peptide transport quantified 
by the amount of glycosylated, radiolabeled peptide was analyzed in the presence of ATP 
or 8-azido-ATP. The accumulation of peptides in microsomes increases linearly within the Chapter 4  Results 
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first 2 min (Fig. 4-1A). The initial transport rates were determined at increasing ATP or 8-
azido-ATP concentrations and fitted with Michaelis-Menten kinetics (Fig. 4-1B). The 
apparent Km values for both nucleotides show only a slight difference, which are 197±35 
µM for ATP and 103± 24 µM for 8-azido-ATP, whereas the Vmax for both nucleotides is 
equal. From these results, we conclude that 8-azido-ATP support peptide translocation as 
efficiently as ATP and modification of the C8 position of the adenine base does not change 
the properties of the nucleotide during the catalytic cycle. 
 
 
Figure 4-1. TAP-dependent peptide transport in the presence of ATP and 8-azido-ATP. A,
Microsomes prepared from insect cells infected with recombinant baculovirus encoding human
TAP1 and TAP2 were incubated with 1 µM radiolabeled RRYQNSTEL at 3 mM of ATP (filled
symbols) or 8-azido-ATP (open symbols) at 32°C for different times. Glycosylated peptides
were recovered by ConA-Sepharose, and the radioactivity was quantified by using γ-counting.
B, Peptide uptake of microsomes was measured at various concentrations of ATP (filled
symbols) or 8-azido-ATP (open symbols) for 2 min. The data were fitted with the Michaelis-
Menten equation leading to a Km value of 197±35 µM for ATP (solid) and 103±24 µM for 8-
azido-ATP (dashed line). Data points and errors were derived from triplicate measurements. Chapter 4  Results 
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4.1.3  8-Azido-ATP binds specifically to TAP1 and TAP2 
Next, we examined the nucleotide binding property of TAP by 8-azido-[α-
32P]ATP 
photocross-linking. After immunoprecipitation, TAP1 and TAP2 (apparent molecular mass, 
71 and 75 kDa) were separated by high resolution SDS-PAGE (Fig. 4-2). The identity of 
the two TAP subunits was confirmed by immuno-precipitation of disassembled TAP1 and 
TAP2 subunits. The photocross-linking is specific, because it was inhibited by 1 mM ATP. 
Interestingly, even after immunoprecipitation of the TAP complex with an anti-TAP1 
antibody, TAP2 shows stronger photolabeling than TAP1. This preferential labeling of 
TAP2 was observed both for TAP derived from Raji cells and for TAP expressed in insect 
cells lacking factors of the MHC loading complex. These results demonstrate that both 
subunits bind 8-azido-ATP specifically, and TAP2 is photolabeled more efficiently than 
TAP1. 
 
4.1.4  Magnesium- and temperature-dependent 8-azido-ATP binding 
Magnesium is well known to be required for ATP hydrolysis by most ATPases. It 
has also been shown that Mg
2+ can have different effects on ATP binding to two subunits 
 
 
Figure 4-2. 8-Azido-[ α-
32P]ATP photocross-linking of TAP. Microsome preparations
(50 µg of protein) from Raji cells or Sf9 insect cells infected with baculovirus encoding
human TAP1/TAP2 were incubated with 1 µM 8-azido-[α-
32P]ATP in the presence or
absence of 1 mM ATP on ice. Proteins were photolabeled by UV irradiation for 5 min.
The two subunits were either co-immunoprecipitated as an intact heterodimeric complex
via TAP1-specific antiserum (1p2) or as dissociated subunits via TAP1- or TAP2-specific
antibodies (1p2 and 2p4). The immunoprecipitated products were analyzed by SDS-PAGE
(11%) and visualized by autoradiography. Chapter 4  Results 
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of an ABC transporter (Matsuo et al., 1999). Therefore, we examined the influence of 
magnesium on 8-azido-[α-
32P]ATP photolabeling of the TAP complex. No photolabeling 
of TAP1 and TAP2 was observed in the absence of magnesium either at 4°C or 37°C, 
indicating that ATP binding to both TAP subunits is magnesium-dependent (Fig. 4-3A). 
Nucleotide binding to the TAP complex is temperature-dependent. At 4°C, photolabeling 
preferentially occurred at TAP2. However, at 37°C, TAP1 and TAP2 are equally labeled, 
and the photolabeling of both subunits is weaker than at 4°C. Peptides slightly stimulate 
the labeling of both subunits (Fig. 4-3B). 
4.1.5   Phosphate analogs trap ADP in TAP1 and TAP2 
The contribution of each NBD to the ATPase activity of TAP cannot be directly 
analyzed by measuring the steady-state release of inorganic phosphate. ATPase inhibitors, 
such as orthovanadate, BeFx, AlFx, or ScFx, are useful tools to elucidate the mechanism of 
ATP hydrolysis by forming a stable Mg•ADP•inhibitor complex after ATP hydrolysis and 
phosphate release arresting the enzyme in the catalytic cycle (Park et al., 1999; Smith and 
Rayment, 1996; Urbatsch et al., 1995b). Therefore, TAP-containing microsomes were 
incubated with 8-azido-[α-
32P]ATP in the presence of different ATPase inhibitors at 37°C 
to test their ability to form a trapped Mg•ADP•inhibitor•TAP complex. After trapping, 
weakly bound nucleotides were removed by washing the microsomes. Photolabeling of 
TAP1 and TAP2 was observed in the presence of all three metal fluorides, whereas very 
weak signals were found in the presence of vanadate (Fig. 4-4). No photolabeling was 
observed in the absence of trapping reagents. Microsomes derived from insect cells 
infected with baculovirus wild-type also showed no photolabeling. The trapping reaction 
was peptide-specific, and this is investigated in detail below. These data demonstrate that 
metal fluorides form a trapped state with ADP within the NBD of TAP1 and TAP2. This 
state is very stable, because trapped ADP cannot be competed out even by a 1000-fold 
excess of ATP. In all cases stronger labeling of TAP1 than TAP2 was observed. In 
summary, the phosphate analogs trap ADP in TAP with the following efficiencies: BeFx> 
ScFx> AlFx> Vi. complex via TAP1-specific antiserum (1p2) or as dissociated subunits via 
TAP1- or TAP2-specific antibodies (1p2  and  2p4). The immuno-precipitated products 
were analyzed by SDS-PAGE (11%) and visualized by autoradiography. Chapter 4  Results 
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Figure 4-4. Analysis of ATPase inhibitors of TAP. Microsomes (50 µg of protein) from insect
cells infected with baculovirus (BV) encoding human TAP1/2 or wild type baculovirus were
incubated with 2 µM 8-azido-[α-
32P]ATP either in the absence or presence of 0.5 mM of different
inhibitors (BeFx, AlFx, ScFx, or orthovanadate) and 1 µM peptide R9LQK for 15 min at 27°C.
After washing and UV-photocrosslinking, samples were subjected to SDS-PAGE (11%) and
visualized by autoradiography. 
 
Figure 4-3. Effect of Mg
2+ and temperature on 8-azido-[α-
32P]ATP photocross-linking. A,
microsomes (100 µg of protein) prepared from Raji cells were incubated with 1 µM 8-azido-
[α-
32P]ATP in the presence or absence of 1 mM MgCl2 or 1 µM R9LQK for 5 min at 4°C or
37°C. Samples at 37°C were transferred on ice, and all probes were immediately subjected to
UV irradiation. The TAP complex was precipitated via anti-TAP1 monoclonal antibody 148.3,
separated by SDS-PAGE (11%), and analyzed by autoradiography. B, to compare the slight
increase in labeling efficiency in the presence of peptide the corresponding TAP1 (filled bars)
and TAP2 (open bars), bands were densitometrically analyzed, and intensities are shown as a
histogram. Chapter 4  Results 
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4.1.6  Peptides induce the formation of a trapped intermediate state 
It has been recently demonstrated that ATP hydrolysis is coupled to peptide binding 
and transport (Gorbulev et al., 2001). However, it remains unclear whether TAP1 or TAP2, 
or both subunits are involved in ATP hydrolysis. Here, we investigated the effect of 
various peptides on BeFx trapping of Mg-8-azido-[α-
32P]ADP by incubating TAP with 8-
azido-[α-
32P]ATP under hydrolyzing conditions. Both subunits were strongly labeled in 
the presence of the high affinity peptide R9LQK and BeFx (Fig. 4-5A). A very weak 
labeling for TAP1 and TAP2 was observed in the presence of the herpes simplex virus 
protein ICP47, which specifically inhibits peptide binding and thus prevents the peptide- 
stimulated ATPase activity of TAP (Ahn et al., 1996; Gorbulev et al., 2001). Furthermore, 
a weak labeling of TAP was found in the presence of the low affinity peptides (Kd>1 mM), 
E9D and D-R9LQK. In the absence of BeFx, no labeling of TAP was detected even when 
high affinity peptides are present. To analyze the peptide-induced formation of a trapped 
intermediate quantitatively, BeFx trapping was performed with increasing concentrations of 
R9LQK. Photolabeling of both TAP subunits was enhanced in a concentration-dependent 
manner (Fig. 4-5B). The EC50 values (peptide concentration required to achieve half-
maximal trapping) for TAP1 and TAP2 are very similar with 16 nM and 18 nM, 
respectively (Fig. 4-5C). These values are in good agreement with the affinity constant of 
fluoresceinlabeled R9LQK (12 nM) measured under equilibrium binding condition 
(Neumann and Tampé, 1999). Interestingly, under all trapping conditions, TAP1 was 
preferentially labeled. Taken together, these data demonstrate that peptides specifically 
induce BeFx trapping of both TAP subunits.  
Figure 4-5. Peptide-induced BeFx trapping of TAP1 and TAP2. (see picture in next page)
Trapping of TAP was performed by incubating Raji microsomes (100 µg of protein) with 2 µM 8-
azido-[α-
32P]ATP in the presence or absence of 0.5 mM BeFx and/or 1 µM of different peptides
(A) or increasing R9LQK concentration (B) To investigate the effect of the viral inhibitor ICP47,
microsomes were incubated with 20 µM ICP47. The TAP complex was immunoprecipitated by
polyclonal antibodies 1p2 and 2p4 and analysed by SDS-PAGE (11%) followed by
autoradiography. To determine the EC50 values for peptide-induced trapping, the photolabeling of
TAP1 and TAP2 was quantified. The background-corrected intensities were plotted against
concentration of R9LQK and fitted with equation I/Imax = [peptide]/(EC50 + [peptide]). The
EC50 values for trapping of TAP1 (open circle and dashed line) and TAP2 (close circles and solid
line) are 18 and 16 nM, respectively (C). Chapter 4  Results 
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4.1.7 BeFx-trapping reflects ATP hydrolysis 
Peptide-induced BeFx trapping of TAP might be due to two different mechanisms: 
(i) BeFx substitutes the released phosphate immediately after ATP hydrolysis, forming a 
stableMg•ADP•BeFx complex within the NBD (forward reaction); (ii) ATP is hydrolyzed 
by ATPases present in the microsomal preparation. Trapping is initiated by binding of 
MgADP to TAP, followed by association of BeFx and by formation of a stable 
NBD•Mg•ADP•BeFx complex (backward reaction). To distinguish between the two 
pathways, we compared BeFx trapping in the presence of the 8-azido-[α-
32P]ATP and 8-
azido-[α-
32P]ADP. The concentration as well as the radioactivity of the two nucleotides 
was kept identical to allow direct comparison of the signal intensities. The high affinity 
peptide R9LQK strongly stimulates the trapping of TAP with 8-azido-[α-
32P]ATP (Fig. 4-
6). Moreover, in the case of 8-azido-[α-
32P]ADP, the trapping efficiency of TAP is not 
peptide-dependent and lower than in the presence of 8-azido-[α-
32P]ATP. Therefore, we 
 
 
 
Figure 4-6. Comparison of 8-azido-ATP and 8-azido-ADP trapping with BeFx. Trapping of
TAP was performed by incubating Raji microsomes (100 µg protein) with 2 µM 8-azido-[α-
32P]ATP (5µCi) or 2 µM 8-azido-[α-
32P]ADP (5 µCi) with or without 0.5 mM BeFx and 1 µM
R9LQK or E9D for 15 min at 27°C. The TAP complex was immunoprecipitated via antibodies
1p2 and 2p4, separated by SDS-PAGE (11%), and visualized by autoradiography. Chapter 4  Results 
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conclude that efficient BeFx trapping of TAP occurs only after ATP hydrolysis and that the 
peptide-induced BeFx trapping directly reflects ATP hydrolysis during the catalytic cycle 
of TAP. 
4.1.8 BeFx-trapped state of TAP 
To characterize the BeFx-trapped state of TAP in more detail, peptide and 
nucleotide binding as well as peptide transport of trapped TAP were analyzed. After 
incubation of microsomes with BeFx and ATP for 15 min, peptide transport via TAP was 
reduced to 20% (Fig. 4-7A). Longer incubation with BeFx blocked the TAP transport 
activity completely. However, longer incubation time also impaired TAP function. The 
stability of the trapping state was examined by monitoring the recovery of peptide 
transport over time. For this purpose, free BeFx was removed to facilitate the dissociation 
of TAP•Mg•ADP•BeFx complex. It was observed that even after incubation for 45 min on 
ice, TAP remains in an inhibited state. Longer recovery times were not analyzed, because 
TAP started to loose activity even at 4°C. Next, we studied the BeFx-trapped TAP complex 
with respect to nucleotide and peptide binding. Fig. 4-7B shows that pretreatment of TAP 
with BeFx and ATP inhibits the photolabeling with 8-azido-[α-
32P]ATP and 8-azido-[α-
32P]ADP, demonstrating that the trapped state of TAP can neither bind nor exchange added 
nucleotides. The weaker photolabeling signal of TAP preincubated with ATP compared 
with that without ATP results from incomplete dissociation of ATP during the washing 
step. In contrast to nucleotide binding, BeFx trapping does not affect peptide binding (Fig. 
4-7C). At half-maximal and saturating peptide concentrations, the amount of peptides 
bound to the trapped and non-trapped state is equal. These data demonstrate that neither 
the affinity nor the overall amount of the peptide-binding sites was altered. In addition, the 
same results were obtained when AlFx and ScFx were used for trapping (data not shown). 
Taken together, BeFx inhibits peptide translocation by trapping TAP in a stable 
intermediate state to which added nucleotides cannot bind. Importantly, peptide binding to 
TAP is not affected in this trapped state. 
 Chapter 4  Results 
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Figure 4-7. Characterization of the BeFx-trapped TAP complex. A, stability of the BeFx-
trapped TAP complex. Raji microsomes (250 µg of protein) were incubated with 1 µM R9LQK,
3 mM ATP in the absence (solid bar) or presence (hatched bar) of 5 mM BeFx at 27°C for
15min. Subsequently, free and un-trapped nucleotides and peptides were removed by washing,
and microsomes were resuspended in transport buffer containing 3 mM ATP and incubated on
ice. After different time periods, peptide transport was initiated by adding 1 µM radiolabeled
RRYQNSTEL and immediately transferring samples to 32°C for 2 min. Translocated peptides
were recovered on ConA beads and quantified by γ-counting. B, binding of nucleotides to the
BeFx-trapped TAP complex. Raji microsomes (100 µg of proteins) were incubated with 1 µM
R9LQK in the presence or absence of 3 mM ATP and/or 5 mM BeFx (Be:F = 1:10 mol/mol) at
27°C for 15 min. After washing the microsomes to remove all free and loosely bound nucleotide
and peptide, microsomes were incubated with 1 µM 8-azido-[α-
32P]ATP or 8-azido-[α-
32P]ADP
for 5 min on ice, followed by UV irradiation. TAP1 and TAP2 were coimmunoprecipitated by a
combination of polyclonal antibodies 1p2 and 2p4. C, peptide binding to the BeFx-trapped TAP
complex. Raji microsomes (250 µg of proteins) were incubated with 3 mM ATP and 1 µM
R9LQK in the absence (solid bar) or presence (hatched bar) of 5 mM BeFx (Be:F = 1:10
mol/mol) at 27°C for 15 min. After washing, peptide binding of radiolabeled R9LQK was
determined. Chapter 4  Results 
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4.2  Two non-equivalent C-loops in the NBDs of TAP 
4.2.1 Introduction 
Peptide transport is strictly ATP-hydrolysis dependent (Neefjes et al., 1993b; 
Shepherd et al., 1993). Both functional NBDs are required for energizing the peptide 
transport process (Arora et al., 2001; Daumke and Knittler, 2001; Karttunen et al., 2001; 
Lapinski et al., 2001; Saveanu et al., 2001). BeFx trapping studies demonstrated that both 
NBDs hydrolyze ATP during peptide translocation (Chen et al., 2003b). In addition, the 
two NBDs behave asymmetrically, the evidence for which came from mutations in the 
Walker A motif that interrupt peptide transport when introduced in TAP2 but show still 
low transport activity if placed in TAP1 (Alberts et al., 2001; Karttunen et al., 2001; 
Lapinski et al., 2001). 
Recent structural and biochemical studies demonstrated that the NBDs dimerize in 
presence of ATP (Chen et al., 2003a; Fetsch and Davidson, 2002; Janas et al., 2003; Loo et 
al., 2002; Moody et al., 2002; Smith et al., 2002b). Two ATPs are sandwiched at the 
interface of both NBDs, and positioned by the Walker A/B motifs and the C-loop of the 
opposite NBD (Fig. 4-8A). In the dimer, the γ-phosphate of ATP is fixed by additional 
hydrogen bonds to the hydroxyl group of the highly conserved serine and the amide of the 
invariant glycine of the C-loop (LSGGQ). Although these studies elucidated structural 
aspects of the symmetric NBD-dimer formation, the functional asymmetry of the NBDs in 
ABC-transporters cannot be explained. 
The functional non-equivalence of the two NBDs of TAP may be reflected in 
variations of the highly conserved consensus sequences. Notably, all differences from the 
canonical sequences of ABC-proteins affect the ATP-binding site I, which is built up by 
the Walker A and B motifs of TAP1 and the C-loop of TAP2 (Fig. 4-8B). Among these 
changes in the ATP-binding site  I, most remarkably, the C-loop of TAP2 contains a 
“ degenerated” sequences LAAGQ instead of conserved LSGGQ. The substitution of the 
highly conserved serine in the C-loop is unique among all human ABC-transporters (Fig. 
4-8C). For this reason, we examined the contribution of the ABC signature motifs to the 
functional asymmetry of the two TAP subunits by single-site mutations and chimeras. Chapter 4  Results 
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Figure 4-8. Structure of the ATP-binding site. A, X-ray structure of one ATP-binding site of
the MJ0769 dimer in complex with Na-ATP (Smith et al., 2002b). One NBD containing Walker
A/B sequence is illustrated in green and the second NBD containing the C-loop is depicted in
yellow. B, Schematic model of the catalytic sites in the ATP-sandwitched dimer of TAP. The
interactions between NBDs and the phosphate groups of ATP are adopted from the structure of
MJ0796 and Rad50 (Hopfner et al., 2000; Smith et al., 2002b). Van der Waals contacts (≤ 3.6Å)
are represented in black lines while H-bonds (≤ 3.3Å) are represented by blue lines. The non-
conserved residues at ATP-binding site I are highlighted in red. C, Sequence alignment of the C-
loops of various human ABC-transporter. The grey frame marks the core sequences of C-loop.  Chapter 4  Results 
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4.2.2  Expression of single site C-loop mutants 
Recently, it was shown that NBDs from both subunits (TAP1 and TAP2) are 
required to assemble a functional TAP transport complex (Arora et al., 2001; Daumke and 
Knittler, 2001). Moreover, ATP hydrolysis in both subunits is stimulated by peptide 
binding (Chen et al., 2003b; Gorbulev et al., 2001). However, different peptide transport 
activities of Walker A mutants indicate a functional asymmetry of both TAP subunits 
(Alberts et al., 2001; Karttunen et al., 2001; Lapinski et al., 2001). Interesting, TAP1 and 
TAP2 also show an asymmetry in their C-loop sequences: LSGGQ in TAP1 versus 
LAAGQ in TAP2. The glycine and serine residue of the C-loop (LSGGQ) contacting the γ-
phosphate of ATP are highly conserved among members of the ABC superfamily (Fig. 4-
8). The other positions (LSGGQ) in the C-loop are however more divergent. To examine 
the functional relevance of two different C-loops in the functional asymmetry of TAP, we 
first focused on the leucine and the highly conserved glycine of the C-loop. The leucine, 
which is not in direct contact with ATP and not as conserved as the remaining residues in 
the C-loop, was exchanged to alanine. In human ABC-transporters, this leucine is replaced 
mostly by bulky aromatic amino acids. In addition, the invariant glycine residue was 
changed to valine or aspartate. In our studies, all mutated half-transporters were combined 
with a wild type counterpart, which resulted in three pairs of mutants. These six TAP 
mutants are termed 1LA/2wt vs 1wt/2LA, 1GV/2wt vs 1wt/2GV, 1GD/2wt vs 1wt/2GD 
(mutated residues of TAP1/TAP2 are underlined). All TAP1 and TAP2 constructs were 
cloned into one baculovirus to circumvent the problem with double infections, and 
expressed in Sf9 insect cells under the control of the polyhedrin and p10 promoter, 
respectively. Three days after infection, cells were harvested and microsomes were 
prepared. As revealed by immunoblotting, all TAP mutants were expressed in microsomes 
at comparable level to wt TAP (Fig. 4-9). The small differences in the expression levels 
were most likely due to variations in microsome preparation or conditions of viral infection. 
Thus these single-site C-loop mutations do not alter the overall expression level of TAP1 
or TAP2.  
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4.2.3  Peptide binding is not influenced by single C-loop mutations 
Peptide binding is a prerequisite for peptide transport (Androlewicz et al., 1994; 
van Endert et al., 1994). Mutations in the Walker A motif of TAP were shown to influence 
peptide binding at the TMD (Alberts et al., 2001; Karttunen et al., 2001; Knittler et al., 
1999; Saveanu et al., 2001). Therefore, we investigated whether these single-site mutations 
in the C-loop have an impact on peptide binding. Binding affinities for the high affinity 
peptide R9LQK (RRYQKSTEL) were determined at 4°C in the absence of nucleotides. As 
shown in Fig. 4-10, the data can be fitted according to a Langmuir 1:1 binding model for 
all TAP variants. All mutants have very similar affinities (Tab. 4-1), demonstrating that the 
C-loop mutations do not modify the structure of the peptide-binding pocket. Moreover, 
because both subunits are essential for peptide binding, these results prove that these 
mutations do not interfere with assembly of the heterodimeric TAP complex. 
4.2.4  ATP binding is not influenced by single C-loop mutations 
In addition to the association with peptides, ATP must bind to energize peptide 
transport by ATP hydrolysis. Mutations in the Walker A sequence of TAP1 or TAP2 
abolished or reduced ATP binding which can explain the defect in peptide transport 
(Karttunen et al., 2001; Lapinski et al., 2001; Saveanu et al., 2001). The contribution of the 
 
 
Figure 4-9. Expression of TAP C-loop single substitution mutants. Western Blot
analysis of microsome preparations from Sf9 insect cells infected with baculovirus encoding
TAP variants. The mouse anti-TAP1 (148.3) and anti-TAP2 (435.3) monoclonal antibodies
were used to detect TAP1 and TAP2 protein expression respectively. Cells transfected with
baculovirus encoding tapasin were used as negative control. Chapter 4  Results 
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Walker A motif in nucleotide binding can be clearly derived from the x-ray structures of 
NBDs. However, the effect of C-loop mutations on nucleotide binding is not obvious 
because singularly expressed TAP subunits bind ATP with similar affinity than the 
heterodimeric complex (Lapinski et al., 2003). Therefore, nucleotide binding of single C-
loop mutants was analyzed by photo-crosslinking with 8-azido-[α-
32P]ATP (1 µM, 4°C). 
All TAP variants can bind 8-azido-[α-
32P] ATP, which can be competed out by an excess 
of unlabeled ATP (Fig. 4-11A). The labeling efficiency of the mutants varies and is lower 
in comparison to wt TAP. Moreover, the ratio between labeled TAP1 and TAP2 has 
changed in comparison to wt TAP. To clarify whether these differences are due to changed 
nucleotide affinities or non-equivalent expression of the two TAP subunits, we compared 
the expression level of each subunit taking TAP wt as a standard. Fig. 4-11B showed that 
in comparison to TAP wt, the ratio of the expression level of TAP2 to TAP1 is reduced for 
all the mutants in dependent of which subunit is mutated. Thus, the stronger labeling at 
TAP1 subunit in the mutants is likely due to its higher expression level. In summary, the 
photolabeling efficiency of TAP mutants is relatively lower than wt TAP. Nevertheless, all 
the C-loop mutants could interact with 8-azido-ATP at a micromolar concentration. Form 
these studies we concluded that these single-site mutations do not prevent the ATP binding 
to TAP. 
 
Table 4-1. Peptide dissociation constants of C-loop mutants of TAP 
TAP1/TAP2 Kd (µM)   
1wt/2wt 0.27±0.06  wild  type 
1LA/2wt 0.50±0.09   
1GV/2wt 0.37±0.13   
1GD/2wt 0.36±0.08 
1wt/2LA 0.41±0.10 
single residue 
substitutions 
1wt/2GV 0.30±0.07   
1wt/2GD 0.21±0.06   
1SG/2SG 0.34±0.02   
1AA/2AA 0.27±0.03  chimeras 
1AA/2SG 0.32±0.05   Chapter 4  Results 
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Figure 4-10. Peptide binding of single C-loop mutants of TAP (previous page).
Microsomes (15 µg protein) of single C-loop mutants were incubated with increasing
concentration of radiolabeled peptide R9LQK (15 min, 4°C). Free peptides were removed
by washing and microsome-associated peptides were determined by γ-counting.
Specifically bound peptides are plotted against the peptide concentration and fitted by a
Langmuir (1:1) binding equation. The peptide affinities are summarized in table 4-1. Data
resemble the mean of three measurements. 
 
Figure 4-11. ATP binding to single residue substitutions of the C-loop of TAP.  A,
Microsomes (100 µg protein) containing different single C-loop mutations were incubated with
8-azido-[α-
32P]ATP (1 µM) in absence or presence of 1 mM ATP at 4°C. Bound 8-azido-[α-
32P]ATP was crosslinked by UV irradiation. Subsequently, TAP was immunoprecipitated with
polyclonal antibodies recognizing TAP1 and TAP2 (1p2 and 2p4), separated by SDS-PAGE
(11%), and visualized by autoradiography. B, Comparison of the expression level of TAP1 and
TAP2. The expression level of the two subunits in TAP mutants was detected by western
blotting and the signal intensity was analysed by lumi-imager. The ratio of the expression level
of TAP2 to TAP1 in these mutants is depicted setting the ratio in wt TAP to 1:1.  
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4.2.5  Non-equivalent effect of single C-loop mutants on peptide transport 
All C-loop mutants described so far show no significant effect on peptide as well as 
ATP binding. Finally, the peptide transport function of these mutants was investigated. In 
vitro peptide transport assays were preformed using isolated TAP-containing microsomes 
and the radiolabeled peptide RRYQNSTEL at 32°C as described (Meyer et al., 1994; 
Neefjes et al., 1993b). To allow a direct comparison, the TAP concentration, determined by 
immunoblotting or peptide-binding (Bmax value), was kept constant in all experiments. In 
contrast to wt TAP, the mutants did not show any peptide transport activity over a period 
of 2  min. Transport assays were then extended to 5  min. Even under these prolonged 
transport periods, the TAP complexes containing TAP1 mutants remained inactive (Fig. 4-
12). However, TAP2 mutants transported peptides albeit with much lower efficiency than 
wt TAP. In addition, there are differences between the mutations introduced in TAP2. The 
1wt/2LA TAP complex transports peptides more efficient than 1wt/2GV, whereas 
1wt/2GD shows the lowest peptide transport activity. Obviously, the position and the type 
 
 
Figure 4-12. Peptide transport of TAP containing single residue substitutions of the C-
loop. Microsomes (100 µg protein) containing different C-loop mutations of TAP were
incubated with 1 µM radiolabeled RRYQNSTEL in the presence of 3 mM ATP (black) or
ADP (hatched) at 32°C for 5 min. Glycosylated peptides were recovered by Con A sepharose
and the radioactivity was quantified via γ-counting. Chapter 4  Results 
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of mutation in the C-loop affect the transport in slightly different manner. As these TAP 
mutants show no difference in peptide as well as ATP binding, the loss of function must be 
related to disabled ATP hydrolysis or inefficient coupling of ATP hydrolysis to transport. 
We conclude that C-loop mutations in TAP1 completely abolish the function of the TAP 
complex, whereas the same substitutions in TAP2 decelerate the transport machinery. 
These findings further support the idea of the functional non-equivalence of both NBDs of 
TAP in the overall transport cycle. 
4.2.6  Expression of C-loop chimera 
Based on the fact that the symmetrical C-loop mutations in TAP1 and TAP2 
described so far behaved differently, we focused on residues of the ABC signature motif 
that vary in TAP1 and TAP2 (LSGGQ versus LAAGQ). For this reason, we studied TAP 
complexes comprising two canonical C-loops motifs (LSGGQ/LSGGQ) named as 
1SG/2SG, switched C-loops (LAAGQ/LSGGQ) as 1AA/2SG and two degenerated C-loops 
(LAAGQ/LAAGQ) as 1AA/2AA (mutated residues are underlined). Microsomes were 
prepared from insect cells infected with recombinant baculovirus. The expression levels of 
all C-loop chimeras are very similar (Fig. 4-13), demonstrating that a degenerated C-loop 
in TAP1 and/or TAP2 does not affect the expression level of TAP.  
4.2.7  Peptide and nucleotide binding of C-loop chimera 
The behavior of the TAP C-loop chimeras was studied following the same 
procedures as for the single residue mutants described above. The TAP C-loop chimeras 
and wt TAP bind peptide with the same affinity (Fig. 4-14/Tab. 4-1). Therefore we 
conclude that similar to the single residue mutants, the switched C-loop chimeras do not 
influence peptide binding. As analyzed in 8-azido-[α-
32P]ATP photo-crosslinking studies, 
all TAP C-loop chimeras bind ATP in a competitive manner (Fig. 4-15A). In contrast to wt 
TAP, TAP1 is stronger labeled than TAP2 for all three chimeras, which is also likely 
caused by its higher expression level. 
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Figure 4-13. Expression of TAP C-loop chimera. Western Blot analysis of microsome
preparations from Sf9 insect cells infected with baculovirus encoding TAP variants. The mouse
anti-TAP1 (148.3) and anti-TAP2 (435.3) monoclonal antibodies were used to detect TAP1 and
TAP2 protein expression, respectively.  
 
 
Figure 4-14. Peptide binding of C-loop chimera. Microsomes (15 µg protein) of C-loop
chimeras were incubated with increasing concentration of radiolabeled peptide R9LQK (15 min,
4°C). Free peptides were removed by washing and microsome-associated peptides were
determined by γ-counting. Specifically bound peptides are plotted against the peptide
concentration and fitted by a Langmuir (1:1) binding equation. The peptide affinities are
summarized in table 4-1. Data resemble the mean of three measurements. Chapter 4  Results 
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4.2.8  Non-identical C-loops induce functional asymmetry 
We next investigated the transport activity of the C-loops chimeras. Interestingly, 
unlike the single residue substitutions of the C-loop described above, all TAP chimeras 
including the construct having two degenerate C-loops (1AA/2AA) are highly active in 
peptide translocation. To detect even subtle differences in peptide-translocation activity, 
initial transport rates were determined. The concentration of functional TAP was 
normalized by peptide binding (Bmax value). ATP-dependent peptide translocation into 
microsomes is peptide-specific and increases linearly over a period of 3 min for all four 
 
 
Figure 4-15. ATP binding to C-loop chimera of TAP.  A, Microsomes (100 µg protein)
containing different single C-loop mutations were incubated with 8-azido-[α-
32P]ATP (1 µM) in
absence or presence of 1 mM ATP at 4°C. Bound 8-azido-[α-
32P]ATP was crosslinked by UV
irradiation. Subsequently, TAP was immunoprecipitated with polyclonal antibodies recognizing
TAP1 and TAP2 (1p2 and 2p4), separated by SDS-PAGE (11%) and visualized by
autoradiography. B, Comparison of the expression level of TAP1 and TAP2. The procedure is
the same as described in figure 4-11B.  Chapter 4  Results 
  60
TAP variants (Fig. 4-16). However, by analyzing the initial transport rates the differences 
in peptide transport became obvious (Table 4-2). The 1SG/2SG variant transported 
peptides with the fastest rate (k = 0.330 cpm/s), which is 115% of the wt TAP. The TAP 
chimera 1AA/2SG harboring the exchanged C-loop (k = 0.262 cpm/s) translocated peptide 
as efficiently as wt TAP (k = 0.287 cpm/s). ). The most drastic effect showed the TAP 
complex with two degenerated C-loops with a 50% reduced transport rate in comparison to 
wt TAP. These results indicate that the C-loop in both TAP subunits controls the peptide-
transport rate by tuning the ATP hydrolysis in both ATP-binding sites. In addition, the C-
loop is at least partially responsible for the functional asymmetry of both NBDs. 
 
 
Figure 4-16. Peptide transport of C-loop chimera. The microsomes expressing TAP C-
loop chimera were adjusted by their peptide-binding capacity, which were then incubated
with 1 µM radiolabeled RRYQNSTEL in the presence of 3 mM ATP or ADP at 32°C
over various periods in a total volume of 50 µL. Glycosylated peptides were recovered by
Con A sepharose and the radioactivity was quantified via γ-counting. ATP-dependent
peptide transport is plotted against time and fitted linearly. The slopes reflect the initial
rate constant for peptide transport and are listed in table 4-2. The data points are the mean
of three measurements. 1SG/2SG (   ); 1wt/2wt (   );  1AA/2SG ( );
1AA/2AA (   ). 
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4.2.9  Effect of ATP on the stability of C-loop mutants 
The TAP complex undergoes rapid denaturation at 37°C, resulting in a drastically 
reduced peptide binding and transport activity (van Endert, 1999). Taking peptide-binding 
ability as readout for TAP function, we analyzed the effect of C-loop mutations on the 
thermal stability of TAP in the absence of nucleotides. Microsomes containing TAP 
variants were incubated for 15 min at 37°C and their remaining activities were analyzed by 
peptide-binding assay. To prevent the interference of the trace-amount ATP or ADP in the 
microsomes, 1 unit apyrase was added. Here, the peptide binding of each TAP variant at 
4°C was defined to 100%. Wild type TAP from Raji cells still showed 65% of peptide-
binding capacity after incubation at high temperature, while only 40% peptide-binding 
sites remained in the wt TAP from Sf9 cells (Fig. 4-17). These results indicate that 
interaction of the TAP complex with tapasin and MHC class I molecule in Raji cells 
increases its thermal stability.  
In comparison to wt TAP from insect cells, all TAP C-loop single mutants 
exhibited a reduced stability. The most severe effect was observed for 1LA/2wt, which lost 
nearly 90% of its peptide-binding ability. Interestingly, two C-loop chimera 1SG/2SG and 
1AA/2SG were as stable as wild type TAP; while the C-loop chimera (1AA/2AA) bearing 
two “degenerated” C-loop resulted in a less stable protein. Taking together, these results 
demonstrate that the mutation of the highly conserved leucine and glycine in the C-loop 
from either subunit impair the stability of the TAP complex. Moreover, TAP containing 
two consensus C-loop (1SG/2SG) or only one consensus C-loop (wt, 1AA/2SG) have 
similar stability at 37°C. The tolerance of the transporter over high temperature decreases 
only when the TAP contains two “degenerate ” C-loops. 
Table 4-2. Peptide transport rates of C-loop chimeras 
 
TAP1/TAP2 k  (cpm/s) 
1wt/2wt 0.287±0.007 
1SG/2SG 0.330±0.010 
1AA/2SG 0.262±0.012 
1AA/2AA 0.147±0.008 
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It was shown by van Endert and his colleagues that ADP and ATP stabilize TAP 
complexes and maintain its peptide-binding ability at 37°C (Saveanu et al., 2001; van 
Endert, 1999). Fig 4-17 shows that the presence of 3 mM ATP preserves the peptide-
binding ability of all TAP mutants at 37°C, however to different extent. 50% peptide-
binding activity remained in all TAP1 C-loop single mutants in the presence of ATP. 
Interestingly, ATP did not have identical effect on the function of all TAP2 single mutants. 
It stabilized the TAP2 glycine mutants (1wt/2GV and 1wt/2GD) to the similar level as the 
wild type, while TAP2 leucine mutant (1wt/2LA) retained only 30% of peptide-binding 
capacity. For the C-loop chimeras, 1SG/2SG still maintains its 100% peptide-binding 
ability in the presence of ATP after incubation at 37°C. Under identical condition, the 
peptide-binding ability of 1AA/2SG is slightly reduced. In comparison, the peptide binding 
of 1AA/2AA is drastically decreased to 60%. Based on these results, we could draw the 
following conclusions: i) ATP could only moderately preserve the full function of all 
TAP1 mutants. ii) the effect of ATP on the stability of TAP2 mutants are diverse. TAP2 
glycine mutants retained the full activity in peptide binding but not the leucine mutants. iii) 
ATP stabilizes TAP chimera containing at least one consensus C-loop to the similar extent 
as wt TAP.  
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Figure 4-17. Stability of TAP variants at 37°C. Microsomes expressing TAP C-loop single
mutants (A) or chimeras (B) were incubated for 15 min at 37°C in the presence of 3 mM ATP
(black bar) or 1 unit apyrase (hatched bar) in 50 µl AP buffer. In parallel, microsomes were
also incubated at 4°C under identical condition for 15 min. Then the mixtures were cooled
down to 4°C and incubated with 1 µM radiolabeled R9LQK peptides for 15 min. Specific
peptide binding was calculated after subtracting the background binding. Setting the peptide-
binding ability of the samples at 4°C as 100%, the retained peptide-binding capacity of each
mutant after incubation at 37°C was depicted. The results are the average of triplicate samples.Chapter 4  Results 
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4.3  Role of the acidic residue downstream of the Walker B motif 
4.3.1 Introduction 
NBDs of ABC transporters catalyze ATP hydrolysis and energize the substrate 
transport. The NBDs contain three highly conserved sequences: the Walker A and B motifs 
and the C-loop, which are essential for ATPase activity. In addition, an acidic residue 
which is a glutamate in most of cases is also highly conserved downstream of the Walker B 
motif. Based on biochemical studies of glutamate to glutamine mutants (referred to as EQ 
mutants in this work) of isolated NBD or full-length ABC transporters (Moody et al., 2002; 
Orelle et al., 2003), this glutamate was proposed to be the catalytic base for the enzymatic 
cleavage of the phosphoanhydride bond. This hypothesis is in concert with the prediction 
derived from the structure alignment of several ATPases and ABC transporters (Geourjon 
et al., 2001; Muneyuki et al., 2000).  
ATP hydrolysis was shown to be strictly controlled by peptide binding and peptide 
transport indicating an allosteric crosstalk between the transmembrane domain and 
nucleotide-binding domains (Gorbulev et al., 2001). It is believed that during the substrate 
transport process extensive communications occur between the substrate-binding site and 
NBDs of ABC transporters. However, only few studies have experimentally addressed the 
link between ATP hydrolysis and substrate-binding sites. In fact, peptide binding to TAP is 
considered to be an ATP-independent process (van Endert et al., 1994).  
Several studies have shown that catalytic transition states can also be stabilized by 
mutation of the conserved glutamate in the NBD instead of using ATPase inhibitors (Janas 
et al., 2003; Moody et al., 2002; Payen et al., 2003). Thus mutation of this residue in TAP 
can be helpful to i) address the coupling process between the ATP binding/hydrolysis and 
the peptide binding and ii) gain more insights in the role of the acidic residue in the ATP 
hydrolysis process. In this study, we have exchanged the conserved acidic residues in 
NBD1 and NBD2 of TAP and expressed the TAP EQ mutants in insect cells using a 
baculovirus dual expression system. The effects of the mutations on peptide binding were 
assessed. Furthermore, we also studied the influence of nucleotide on the peptide-binding 
ability of the mutants. Finally, the effects of mutations on the transport activity of the TAP 
were examined.  Chapter 4  Results 
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4.3.2  Expression of TAP EQ mutants 
The glutamate downstream to Walker B motif is highly conserved in human ABC 
transporters (see Appendix 9.2). However, exceptions were found for the ABCC subfamily, 
with CFTR and MRP1 as representatives. In this subfamily, the glutamate is invariably 
substituted by an aspartate in NBD1. Surprisingly, TAP1 and TAP2 (ABCB2 and ABCB3) 
also show this sequence arrangement, thereby distinguishing themselves from other ABCB 
subfamily members. In order to investigate the function of the acidic residues in the TAP 
complex, the aspartate in TAP1 (VLILDD) was mutated to asparagine and glutamine 
(VLILDN, VLILDQ); while the glutamate in TAP2 (VLILDE) was exchanged to 
glutamine (VLILDQ). The single mutant subunit was constructed into a baculovirus dual 
expression system together with either wild type or the mutated opposite subunit to form a 
heterodimeric transporter. Mutants harboring either single or double mutations were 
expressed in Sf9 cells, which are termed 1DN/2wt, 1DQ/2wt and 1wt/2EQ for single 
mutants, 1DN/2EQ, and 1DQ/2EQ for double mutants. All TAP constructs are summarized 
as EQ mutants despite of the aspartate in TAP1.  
The expression levels of the TAP EQ mutants in microsomes isolated from infected 
cells were determined by SDS-PAGE and Western blotting, using the monoclonal 
antibodies 148.3 and 435.4 to detect TAP1 and TAP2, respectively. Microsomes from 
insect cells infected with a tapasin baculovirus construct were used as a negative control. 
 
 
Figure 4-18. Expression of TAP EQ mutants. Microsomal proteins (5 µg) from baculovirus
infected Sf9 insect cells were separated with SDS-PAGE (9%) and analysed by Western-blot
with anti-TAP1 (148.3) or anti-TAP2 (435.3) antibody. As negative control microsomes
containing tapasin were used.  Chapter 4  Results 
  66
As shown in Fig. 4-18, all EQ mutants were expressed in Sf9 cells at a comparable level to 
the wild type protein. 
4.3.3  Peptide binding of EQ mutants at 4°C 
The effect of mutations on the peptide-binding ability of TAP was examined. 
Microsomes containing TAP variants were incubated with increasing concentrations of 
radiolabeled R9LQK at 4°C for 15 min. The mixture was added to filter plates followed by 
the standard procedure as described in section 3.4.5. As shown in Fig. 4-19, the data were 
fitted by the Langmuir (1:1) binding equation and the peptide dissociation constants Kd as 
well as the maximal peptide-binding capacity Bmax of each protein were obtained. All the 
constants are summarized in Tab. 4-3. The Bmax value of each construct indicates the 
amount of functional TAP complexes presented in the experiments. The Kd values of all 
TAP proteins are quite similar, demonstrating that substitution of the putative catalytic 
base of TAP1 and TAP2 does not alter the peptide-binding affinity.  
At 4°C, EQ mutants of several nucleotide-binding domains of ABC transporters 
can be arrested in a dimeric transition state upon ATP binding, resulting in a sandwich 
dimer containing two ATPs (Janas et al., 2003; Moody et al., 2002; Verdon et al., 2003). It 
was postulated that such an ATP-driven dimerization step mediates the structural 
rearrangement of the transmembrane domains (Locher et al., 2002; Moody et al., 2002; 
Smith et al., 2002b). Here we addressed the question, whether nucleotide binding to TAP 
EQ mutants induces any changes in the peptide-binding site located in the transmembrane 
domain. Thus, the peptide-binding affinity of all constructs was determined in the presence 
of 3 mM ATP or ADP. The results are depicted in Fig. 4-19 and the obtained constants are 
summarized in Tab. 4-3. Consistent with previous observations, wild type TAP binds 
peptide with the same affinity in the presence or absence of nucleotides (Neumann and 
Tampé, 1999; Uebel et al., 1995). In contrast to our expectation, nucleotides did not show 
significant influence on the peptide-binding affinity of all five mutated proteins. These 
results suggest that the peptide-binding affinity of the TAP complex was not changed in 
the ATP-ATP dimeric state of the NBDs. Chapter 4  Results 
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Figure 4-19. Peptide binding of EQ mutants at 4°C. Microsomes (15µg protein) containing
TAP mutants were incubated with an increasing concentration of radiolabeled R9LQK in 50 µl AP
buffer in the absence or presence of 3 mM ATP/ADP at 4°C for 15 min. Free peptides were
removed by washing three times with 150 µl ice cold AP buffer and microsome-associated
peptides were determined by γ-counting. Specifically bound peptides in the absence of nucleotides
( ), or presence of 3 mM ATP ( ) or 3 mM ADP ( ) are plotted against the peptide
concentration and fitted by the Langmuir (1:1) binding equation. Data resemble the mean of
triplicate measurements. Chapter 4  Results 
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4.3.4  Peptide binding of EQ mutants at 27°C 
EQ mutants of Mdl1 NBD were shown to be arrested in a dimeric transition state 
containing one ATP and one ADP after being incubated under ATP hydrolysis condition 
(Janas et al., 2003). This ATP-ADP dimeric state occurs after the ATP-ATP dimeric state 
in the ATP hydrolysis cycle. Since in the ATP-ATP dimeric state, the peptide-binding site 
of TAP remains the same as in its ground state, a question arises: is the peptide-binding 
site of TAP complex altered in the ATP-ADP dimeric state? To trap TAP EQ mutants in an 
ATP-ADP dimeric state, microsomes containing TAP EQ mutants were incubated at 27°C 
with 20 nM peptides R9LQK in the presence of nucleotides for 30 min. Then radiolabeled 
R9LQK with increasing concentrations were added to the microsomes to determine their 
peptide-binding ability at 27°C. Although peptide transport can occur under experimental 
condition, it doesn’t disturb the peptide-binding assay because R9LQK without a 
glycosylation sequence cannot accumulate inside the microsomes. The results are shown in 
Fig. 4-20 and all affinity constants were summarized in Table 4-4. 
Similar to the results at 4°C, nucleotides did not significantly affect peptide 
dissociation constants of all six TAP variants at 27°C. In contrast, Bmax values of TAP 
complexes differed in the presence or absence of nucleotides (Fig. 4-21). In the presence of 
nucleotides, wild type TAP showed a higher Bmax than in the absence of nucleotides. 
 
Table 4-3. Summary of peptide binding constants of TAP EQ mutants at 4°C. 
 
No nucleotide  ATP  ADP 
Protein 
Kd (µM) 
Bmax 
(cpm/1000) 
Kd (µM) 
Bmax 
(cpm/1000) 
Kd (µM) 
Bmax 
(cpm/1000) 
1wt/2wt  0.123±0.010 11.8±0.2 0.138±0.009 12.4±0.2 0.142±0.012 11.6±0.3 
1DN/2wt  0.215±0.007 26.3±0.2 0.216±0.027 24.3±1.0 0.215±0.021 22.7±0.8 
1DQ/2wt  0.142±0.012 15.4±0.2 0.145±0.010 14.3±0.3 0.200±0.026 13.4±0.8 
1wt/2EQ  0.131±0.018 11.0±0.3 0.168±0.010 10.4±0.1 0.146±0.018 9.8±0.3 
1DN/2EQ  0.127±0.018 5.3±0.2 0.95±0.035 5.5±0.3 0.128±0.022 4.6±0.2 
1DQ/2EQ  0.190±0.014 3.6±0.1 0.130±0.019 4.4±0.1 0.190±0.024 3.3±0.2 Chapter 4  Results 
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Figure 4-20. Peptide binding of EQ mutants at 27°C. Microsomes (15 µg protein) containing
TAP mutants were incubated with 20 nM R9LQK in the absence of nucleotides ( ) or in the
presence of 3 mM ATP (  ), 3 mM ADP ( ) at 27°C in 45µL AP buffer for 30 min.
Afterwards, 5 µl increasing concentrations of iodinated R9LQK was added to the mixture, which
were incubated at 27°C for 5 min. Free peptides were removed by washing three times with 150
µl ice cold AP buffer and microsome-associated peptides were determined by γ-counting.
Specifically bound peptides are plotted against the peptide concentration and fitted by a Langmuir
(1:1) binding equation. Data resemble the mean of triplicate measurements. Chapter 4  Results 
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Similar results were observed for single TAP1 mutants (1DN/2wt, 1DQ/2wt). It was 
previously shown that binding of nucleotides stabilizes TAP at high temperature (van 
Endert, 1999). Since incubation of microsomes at 27°C for 30 min denatures TAP 
gradually, the higher Bmax in the presence of nucleotides could be due to their increased 
stability. Strikingly, both ATP and ADP caused a reduced Bmax value by 20% for TAP2 
 
 
Figure 4-21. Effect of nucleotides on the peptide binding ability of EQ mutants. Bmax of
each TAP mutant derived from Fig. 4-19 and Fig. 4-20 are shown. The Bmax value of each TAP
variants in the absence of nucleotides was set to 100%. The ratios of the Bmax in the presence of
3 mM ATP (hatched) or 3 mM ADP (gray) to the sample in the absence of nucleotides (black)
are depicted. 
Table 4-4. Summary of peptide binding constants of TAP EQ mutants at 27°C. 
 
No nucleotide  ATP  ADP 
Protein 
Kd (µM) 
Bmax 
(cpm/1000)
Kd (µM) 
Bmax 
(cpm/1000)
Kd (µM) 
Bmax 
(cpm/1000) 
1wt/2wt  0.106±0.010 3.4±0.1 0.128±0.027 4.8±0.2 0.089±0.010 4.4±0.1 
1DN/2wt  0.442±0.040 26.3±1.0 0.430±0.052 31.1±1.4 0.463±0.050 29.6±1.4 
1DQ/2wt  0.282±0.051 18.1±1.1 0.213±0.018 21.0±0.4 0.180±0.012 19.8±0.8 
1wt/2EQ  0.209±0.034 4.6±0.2 0.230±0.027 2.7±0.1 0.221±0.051 3.1±0.3 
1DN/2EQ  0.190±0.0353 5.0±0.2 0.220±0.023 4.2±0.2 0.191±0.023 4.4±0.2 
1DQ/2EQ  0.190±0.038 17.7±0.5 0.130±0.033 13.7±0.6 0.192±0.022 13.6±0.3 Chapter 4  Results 
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single mutation (1wt/2EQ) and TAP mutants with double mutations (1DN/2EQ and 
1DQ/2EQ). Such negative regulatory effect was only observed at 27°C (Fig. 4-20). This 
data suggested that part of TAP complexes with mutant TAP2 subunits might turn to a 
conformation in which peptide binding is abolished.  
  In addition, the peptide dissociation constants determined at 4°C or 27°C are quite 
similar for all TAP variants except for TAP1DN/2wt. This mutant showed a two-fold 
increased Kd value at 27°C compare to 4°C. This might be due to too high concentration of 
TAP complex (ligand) in the reaction. In this case, the prerequisite condition 
([substrate]>>[ligand]) to fit the data by the Langmuir (1:1) binding equation is not met. 
4.3.5  Peptide binding kinetics 
As another means of evaluating the influence of nucleotide on peptide binding, a 
fluorescence quenching assay was applied to study peptide-binding kinetics (Neumann and 
Tampé, 1999). Fluorescein is very sensitive to the polarity or pH of the environment. Thus 
the time-dependent change of fluorescence emission was analyzed during the binding and 
dissociation of fluorescein-labeled peptide to TAP. When microsomes are added to the 
solution containing fluorescein-labeled peptide RRYC(Fluo)KSTEL, a decrease of the 
fluorescence signal is observed. Adding a 400-fold molar excess of non-labeled peptide 
(competitor) releases bound fluorescein-labeled peptides, leading to a time-dependent 
increase of the fluorescence signal. A typical experiment is shown in Fig. 4-22A. The 
association and dissociation, represented by the decrease and recovery of the fluorescence 
signal, can be fitted by monoexponential function (Fig. 4-22B) and the dissociation rate 
constant kdis can be deduced. 
To investigate the effect of the mutation on peptide-binding kinetics, the mutant 
1DQ/2EQ was selected and compared with wild type TAP. The dissociation rate constants 
kdis for wt and 1DQ/2EQ mutants under different conditions are presented in Table 4-5. At 
4°C, peptide dissociation rate constants of wild type TAP and 1DQ/2EQ are quite similar 
in the presence or absence of nucleotides. Thus, we can conclude that at 4°C neither the 
binding of nucleotides nor mutation of the glutamate (aspartate) affects the peptide 
dissociation rate of TAP.  
At 27°C, peptide dissociation rate constant of wt TAP increases to different extent 
varying from 2.5 to 6 fold depending on the presence or absence of nucleotides. This result Chapter 4  Results 
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demonstrated that increasing temperature accelerated peptide dissociation from TAP. In 
comparison to the value with ADP or no nucleotides, kdis decreases by approximate 50% in 
the presence of ATP or ATP•Mg
2+. The Mg
2+ cation did not show an influence on the 
peptide binding rate, indicating that both ATP binding and hydrolysis slowed down the 
peptide dissociation from TAP to the same extent.  
As for the TAP 1DQ/2EQ at 27°C, the kdis also increases by a factor of 3 to12. 
Similar to wild type TAP, ATP binding and/or hydrolysis also slow down the dissociation 
of peptides from 1DQ/2EQ. In addition, mutants show nearly identical kdis values as the wt 
TAP under ATP binding/hydrolysis conditions (ATP/ATP•Mg
2+). Dissociation rate 
constants of 1DQ/EQ were slightly larger than that of wt TAP in the presence of ADP or 
no nucleotides, suggesting that the mutant 1DQ/2EQ undergoes relatively faster peptide 
dissociation under these conditions. Taken together, we concluded that ATP binding and/or 
hydrolysis induce a slower dissociation rate at high temperature for both wt TAP and 
mutant 1DQ/2EQ. Moreover, the kdis constants of wt TAP and 1DQ/2EQ do not show 
drastic differences under all conditions, indicating that the mutation does not have a strong 
influence on the peptide dissociation rate. 
 
Figure 4-22. Peptide binding kinetics studied by fluorescence quenching. A, The fluorescence
emission was recorded at 470/515 nm (excitation/emission) after mixing TAP-containing
microsomes with 20 nM RRYC(Fluo)KSTEL in the presence or absence of nucleotides at 4°C or
27°C (see Methods). The concentrations of TAP and total protein were 2 nM and 100 µg/ml,
respectively. Dissociation of bound peptide from the TAP complexes was induced by adding a
400-fold molar excess of non-labeled RRYQKSTEL. B, The time-dependent change of
fluorescence signal was fitted with monoexponential function (Section 3.4.6) to obtain the
dissociation rate constants (solid line). Chapter 4  Results 
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4.3.6  Peptide transport activity of TAP mutants 
To study the effect of the EQ mutation on the function of TAP, peptide uptake by 
microsomes from Sf9 cells expressing wild type and mutant TAP was determined at 32°C 
for 2 min. The total amount of TAP in each TAP variant was normalized by peptide-
binding assays in order to compare their activity. As shown in Fig. 4-23, substitution of the 
aspartate residue in TAP1 (1DN/2wt) with asparagine does not show any effect on peptide 
transport activity. In comparison, a glutamate at this position (1DQ/2wt) leads to a 
decrease in peptide translocation by 40%. The equivalent mutation at TAP2 (1wt/2EQ) 
showed similar reduced activity. Surprisingly, although the transport activity was more 
severely impaired in the constructs containing double mutations at both subunits 
(1DN/2EQ and 1DQ/2EQ), the transport activity of these two variants still retained 30% of 
the wild type level. In summary, all the TAP EQ mutants except for TAP 1DN/2wt show a 
reduced transport activity. However, the activities of the TAP constructs bearing double 
mutations are not completely abolished. These results demonstrate that the acidic residue 
adjacent to Walker B site is not essential for TAP function. 
Table 4-5. Peptide binding dissociation rate constants.
* 
kdis (s
-1×10
3) 
Protein Condition 
4°C 27°C 
-  5.62±0.54 30.40±1.71 
ATP  7.52±0.36 18.52±1.50 
ATP•Mg
2+  5.26±0.72 16.64±2.16 
wt 
ADP  5.59±0.27 37.31±1.08 
-  5.26±0.65 45.45±3.73 
ATP  6.41±0.82 19.92±3.14 
ATP•Mg
2+  5.32±0.38 17.89±2.31 
1DQ/2EQ 
ADP  4.44±0.32 61.34±1.25 
 
*Numbers listed are the average calculated from triple experiments Chapter 4  Results 
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4.3.7   Effect of EQ mutations on peptide transport kinetics 
Peptide transport by TAP consists of three steps (Abele and Tampé, 1999; Lankat-
Buttgereit and Tampé, 2002): i) ATP binding to TAP; ii) peptide binding to TAP; iii) 
peptide transport.  
So far, no kinetic data has been reported for ATP binding to ABC transporters, 
which occurs likely within the millisecond time. At the concentration of 3 mM of ATP, 
peptide transport is predominantly controlled by peptide binding and subsequent transport 
process. Thus we propose a two-step transport process: i) binding of peptide to TAP that is 
already preloaded with ATP; ii) translocation of peptide through the ER membrane. 
The initial peptide transport rates of wild type and mutant (1DN/2EQ) TAP were 
determined at increasing concentrations of peptide RRYQNSTEL at 32°C. Data of both 
 
 
Figure 4-23. Peptide transport activity of TAP EQ mutants. Microsomes containing different
mutants were incubated with 1 µM radiolabeled RRYQNSTEL in the presence of 3 mM ATP or
ADP at 32°C for 2 min. Transported peptides were recovered by Con A sepharose and the
radioactivity was quantified by γ-counting. ATP-dependent peptide transport was calculated by
subtracting the radioactivity of the ATP samples from the ADP samples. The amount of TAP
mutants in the reaction was normalized by their peptide-binding sites. Data resemble the mean
of triplicate measurements. Chapter 4  Results 
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TAP variants could be fitted by Michaelis-Menten equation and the results are depicted in 
Fig 4-24. To distinguish the Km value for the two substrates (peptides and nucleotides), we 
defined here the Km value for peptides as Km, pep. Interestingly, the calculated Km, pep of 
wild type (1.43 µM) is around two times higher than that of 1DN/2EQ (0.65 µM). 
Since the peptide-binding affinities (Kd=k2/k1) of both proteins in the presence of 
ATP are quite similar, the difference in the Km values can be explained by the reduced k3 
value for the TAP mutant 1DN/2EQ. In the Michaelis-Menten model, the k3 is the turnover 
number, which is directly related to the activity of an enzyme. The calculated k3 for wt 
TAP (0.140 s
-1) is 4 times higher than mutant 1DN/2EQ (0.034 s
-1), which is in good 
agreement with the ratio from transport activity. In summary, by kinetic analysis we 
showed the turnover number of TAP complex is reduced by a factor of 4 after eliminating 
the acidic residue downstream of both Walker B sites. 
4.3.8  Effect of divalent cations on peptide transport 
It is well known that divalent cations are an essential cofactor for ATPases in 
enzymatic cleavage of the phosphoanhydride bond (Cohn, 1990; O'Rourke, 1993). Mg
2+ 
 
 
Figure 4-24. Peptide transport kinetics of TAP complexes. Microsomes (100 µg protein)
containing TAP wide type (A) or 1DN/2EQ (B) were incubated with 3 mM ATP or ADP at
increasing concentrations of RRYQNSTEL at 32°C for 2 min. Transported peptides were
recovered by concanavalin A sepharose, and the radioactivity was quantified by γ-counting.
ATP-dependent transported peptides were calculated by subtracting the signal of ADP
samples from the ATP samples. The data were fitted with the Michaelis-Menten equation
V=Vmax*C/(Km,pep+C) leading to a Km,pep value of 1.434±0.118µM for wild type TAP and
0.650±0.099 µM for TAP 1DN/2EQ. Data points were derived from triplicate measurements. Chapter 4  Results 
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serves this role in most biological systems (Cohn, 1990; O'Rourke, 1993). Other divalent 
cations (e.g. Mn
2+, Ca
2+) can substitute for Mg
2+ in this respect, albeit to different extent 
(Cohn, 1990; Morbach et al., 1993; Urbatsch et al., 1994). Thus, we were interested in 
determining whether the acidic residues of TAP1 (D668) and TAP2 (E632) may be 
involved in forming a complex with cations, as well as whether mutations affect the 
selectivity of cations. To address these questions, the peptide transport efficiency in the 
presence of different divalent cations was analyzed. As shown in Fig 4-25, wild type TAP 
transported peptides most efficiently in the presence of Mn
2+. The ability of other cations 
to support peptide transport decreases in the following order: Mg
2+>Co
2+>Ni
2+. Cu
2+ and 
Zn
2+ failed to catalyze the ATP hydrolysis by TAP. 1DQ/2EQ follows similar rules in 
choosing a cation as the wild type protein with a slight preference for Co
2+ over Mg
2+. 
However, the whole specificity profile for selecting cations was not changed by 
introducing neutral residues, indicating the acidic residue is not involved in complexing the 
divalent cation.  
Although ABC transporters show a reduced ATP-binding in the absence of cation 
(Cai et al., 2002; Chen et al., 2003b), submilimolar concentrations of ATP were sufficient 
to bind isolated EQ NBDs and subsequently induce the dimerization in the absence of 
cation (Janas et al., 2003; Moody et al., 2002; Verdon et al., 2003). Peptide transport of 
TAP 1DQ/2EQ is dependent on divalent cations, suggesting that ATP-binding alone is not 
able to support the peptide translocation. TAP must undergo ATP hydrolysis to pump the 
peptides through the ER membrane. 
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Figure 4-25. Effect of divalent cations on peptide transport. Microsomes (200 µg protein)
containing (A) TAP wt or (B) 1DQ/2EQ were incubated with 1 µM radiolabeled RRYQNSTEL
in the presence of 3 mM ATP or ADP and 5 mM divalent cations (MgCl2, CoCl2, MnCl2, NiCl2,
CuCl2 and ZnSO4) in 50 µl PBS buffer, pH 7.0 at 32°C for 2 min. Transported peptides were
recovered by Con A sepharose and the radioactivity was quantified by γ-counting. Data resemble
the mean of triplicate measurements. Chapter 5    Discussion 
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5. Discussion 
5.1  Two catalytically active NBDs of TAP 
In the last decade, major advances have been made in the study of the mechanism of 
peptide transport by TAP: (i) the peptide specificity and the peptide-binding mechanism of 
TAP were deciphered in detail (Neumann et al., 2002; Neumann and Tampé, 1999; Uebel 
et al., 1997); (ii) the importance of the nucleotide-binding domains of TAP for peptide 
transport was shown by mutation analysis (Alberts et al., 2001; Karttunen et al., 2001; 
Knittler et al., 1999; Lapinski et al., 2001; Saveanu et al., 2001); and (iii) the allosteric 
coupling between peptide binding, ATP hydrolysis and peptide transport was observed 
with reconstituted TAP (Gorbulev et al., 2001). However, the contribution of each subunit 
in the TAP complex to ATP hydrolysis was not characterized up to now.  
By using the technique of BeFx trapping of 8-azido-[α-
32P]ATP followed by 
photolabeling, immunoprecipitation and separation of the TAP subunits by high resolution 
SDS-PAGE, we analyzed the ATPase activity of TAP1 and TAP2 for the first time. Using 
the ATPase inhibitor BeFx formation of a stable complex consisting of Mg•ADP•BeFx 
bound to NBD was achieved. For myosin, a trapping of MgADP by BeFx longer than 3 
days is reported (Maruta et al., 1993). Restricted by the instability of TAP, we showed that 
the trapped TAP complex is at least stable for 45 min. We showed that BeFx trapping of 
TAP is peptide-specific. High affinity peptides induced nucleotide trapping of both 
subunits of TAP in a concentration-dependent manner. This reflects the peptide-stimulated 
ATPase activity of the TAP complex reported in earlier work (Gorbulev et al., 2001). 
Although these previous results demonstrated that peptide binding correlates with ATP 
hydrolysis, we now provide evidence that ATP hydrolysis at both subunits is induced by 
peptides with an EC50 corresponding to the affinity of the peptide. These observations are 
in line with the model that peptide binding to TAP is responsible for a dramatic structural 
rearrangement (Neumann et al., 2002) that triggers ATP hydrolysis by the NBDs of TAP1 
and TAP2 resulting in peptide translocation. The low amount of trapping in the absence of 
peptide or in the presence of low affinity peptides could result from a low intrinsic ATPase 
activity of TAP. However, in the presence of US6, which blocks ATP binding, no 
reduction of background ATPase activity could be observed excluding an intrinsic ATPase 
activity of TAP (Kyritsis et al., 2001). Therefore, background trapping probably caused a Chapter 5    Discussion 
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backward reaction, in which 8-azido-[α-
32P]ADP produced by other ATPases is bound and 
trapped at TAP. This point is supported by the observation that trapping of 8-azido-ADP 
results in the same labeling efficiency of TAP as with 8-azido-ATP in the presence of the 
viral inhibitor ICP47, which blocks peptide binding to TAP.  
The trapped state can be formed independently of ATP hydrolysis, as indicated in 
the studies of Pgp, MRP6, and myosin, which were trapped from an ADP binding state 
(backward reaction) by vanadate or metal fluorides in the absence of ATP hydrolysis (Cai 
et al., 2002; Sauna et al., 2001b; Werber et al., 1992). With low efficiency, BeFx also traps 
TAP from an ADP binding state. Importantly, however, the trapping of 8-azido-ADP is not 
affected by peptides. These observations are in line with studies on Pgp showing that 
trapping without ATP hydrolysis is energetically less favorable. Substrate-induced trapping 
of Pgp is only achieved after ATP hydrolysis and is strongly inhibited in presence of ADP 
(Sauna et al., 2001a; Sauna et al., 2001b). Surprisingly, the trapping efficiency of TAP by 
orthovanadate is very low in comparison to BeFx. Similar results are reported for MRP6, 
where BeFx traps ADP very efficiently and vanadate could only trap ADP in presence of 
Ni
2+ (Cai et al., 2002). The trapping efficiencies of phosphate analogs can be discussed by 
comparing the x-ray structures of myosin in complex with Mg•ADP•BeF4
2-, 
Mg•ADP•AlF4
-, and Mg•ADP•Vi (Fisher et al., 1995; Smith and Rayment, 1996). The 
Vi/AlF4
+-inhibited complexes reflecting most probably the myosin•Mg•ADP-Pi transition 
state were very similar, and the distance between Al/V and the bridging oxygen of the γ-
phosphate group of ADP was 2.0 Å for AlF4
- and 2.1 Å for Vi. However, in the BeFx-
trapped state, which resembles the ground state before ATP hydrolysis occurs, the distance 
between BeFx and the bridging oxygen was only 1.6 Å. Based on this knowledge, the 
differences in trapping MgADP to TAP were probably caused by small structural 
differences in the ATP-binding pocket, in which Mg•ADP•BeFx fits well forming a stable 
complex. 
The crystal structure of the monomeric NBD of TAP1 is highly similar to other 
NBDs of ABC transporters (Gaudet and Wiley, 2001). The structure of the E171Q mutant 
of MJ0796 and the orientation of the NBDs of the vitamin B12 transporter BtuCD 
resemble the Rad50 dimer in which the ATP binding pocket is formed from the Walker A 
and B sequences of one subunit and the C-loop of the other subunit (Hopfner et al., 2000; 
Locher et al., 2002; Smith et al., 2002b). We propose that this dimer structure represents a Chapter 5    Discussion 
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physiological intermediate that occurs transiently during the transport cycle when ATP is 
bound. Therefore, in the trapped state, the NBDs of TAP should be closely associated 
resembling the structure of the NBD dimer. This could explain that, in the trapped state, 
TAP neither binds nor exchanges nucleotides. This observation is in agreement with 
soluble expressed NBDs of the structural and functional TAP homolog MDL1p, a 
homodimeric ABC peptide transporter located in the inner mitochondrial membrane. The 
NBDs of MDL1p form stable BeFx-trapped dimers after ATP hydrolysis. The BeFx-
trapped NBD dimer contains two ADP molecules, which cannot be exchanged by 
nucleotides (Janas et al., 2003). With the structure of the NBD dimer in mind, it is 
surprising that both TAP subunits show different labeling efficiency. At 4°C, TAP2 shows 
stronger 8-azido-ATP photolabeling than TAP1. This difference reflects the 2-fold higher 
affinity of TAP2 (2.7 µM) for 8-azido-ATP than TAP1 (4.6 µM) as reported recently 
(Lapinski et al., 2003). However, in the BeFx-trapped state, TAP1 is more strongly 
photocross-linked than TAP2. The possibility that trapped 8-azido-ADP bound to the 
Walker A site of TAP2 photoreacts with the C-loop of TAP1 is very unlikely, because it 
was shown that trapped 8-azido-[α-
32P]ADP is photocrosslinked to a tyrosine residue of P-
gp, which is highly conserved throughout ABC transporters and forms π- π interactions 
with the adenine ring (Gaudet and Wiley, 2001; Hung et al., 1998; Sankaran et al., 1997; 
Smith et al., 2002b). Furthermore, it is very unlikely that the different signals of trapped 
nucleotide arise from different ATPase activities of both subunits during peptide transport. 
In this case TAP1 should hydrolyze more ATP than TAP2, which is in contrast to the 
cooperativity between both NBDs as reported for other ABC transporter (Davidson and 
Sharma, 1997; Liu et al., 1997; Senior and Bhagat, 1998). Therefore, kinetic or structural 
differences between both ATP-binding sites must likely be the reason for the different 
labeling efficiencies. One possibility is that two ATPs are hydrolyzed within the dimer 
during peptide transport; TAP2 might release ADP faster than TAP1 resulting in a lower 
trapping yield. Another possibility is that the two nucleotide-binding sites differ slightly 
resulting in a more stable Mg•ADP•BeFx complex for TAP1 than for TAP2.  
In this study, we demonstrate that BeFx traps ADP in TAP1 and TAP2 after 
peptide-stimulated ATP hydrolysis. However, we could not decide whether one or two 
nucleotides are fixed within the heterodimeric TAP complex at the same time. Principally, 
two possibilities are found for the trapped state of ABC transporters: (i) both subunits have Chapter 5    Discussion 
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tightly bound nucleotides in the trapped state, or (ii) only one nucleotide is associated with 
the ABC transporter after trapping. In the case of the chloride channel CFTR, an occlusion 
of NBD1 with 8-azido-[α-
32P]ATP is observed that can be enhanced under vanadate 
trapping conditions that also strongly traps 8-azido-[α-
32P]ADP to NBD2 (Szabo et al., 
1999). Consequently, in the trapped state, one ADP and one ATP are bound to NBD2 and 
NBD1 of CFTR, respectively. In contrast, only one ADP is bound to P-gp and the maltose 
permease in the vanadate-trapped state (Chen et al., 2001; Qu and Sharom, 2001). These 
differences in trapping are also reflected in the effect of mutations of the highly conserved 
lysine in Walker A sequence. Mutation of any NBD of the classic ABC transporters TAP, 
P-gp, and maltose permease has severe effects on transport or ATPase activity, whereas the 
same mutation in NBD1 of CFTR does not inhibit significantly the gating (Alberts et al., 
2001; Karttunen et al., 2001; Knittler et al., 1999; Lapinski et al., 2001; Saveanu et al., 
2001). A high and low affinity substrate-binding site has been proposed for several drug 
ABC transporters during the transport process (Sauna and Ambudkar, 2000; van Veen et 
al., 2000). Interestingly, the amount of peptide-binding sites and the peptide affinity of 
TAP are not altered in the BeFx-trapped intermediate. These data suggest that the peptide 
has already been translocated across the membrane. 
In summary, we provide direct evidence that both NBDs of the TAP complex are 
active in ATP hydrolysis during the peptide transport process. In line with previous 
studies, the asymmetric pattern of photolabeling under BeFx-trapping conditions indicates 
the distinctive properties of TAP1 and TAP2 with respect to ATP binding and hydrolysis 
(Alberts et al., 2001; Karttunen et al., 2001; Knittler et al., 1999; Lapinski et al., 2001; 
Saveanu et al., 2001). Combining the newly established BeFx trapping of TAP with 
mutations influencing ATP hydrolysis or peptide transport, the exact role of the two NBDs 
in TAP function can be addressed. 
 
5.2   Non-equivalent C-signature motifs in TAP 
Recent studies have provided some evidence that both TAP subunits act 
asymmetrically in the transport cycle (Alberts et al., 2001; Karttunen et al., 2001; Lapinski 
et al., 2001; Saveanu et al., 2001). However, the origin for this functional non-equivalence 
is still an open question. Therefore we investigated the contribution of the ABC signature Chapter 5    Discussion 
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motif to the functional asymmetry of the TAP subunits by single-site mutants and chimeras 
of the C-loop.  
Single-site mutations of the C-loop in TAP1 or TAP2 effect TAP function to a 
different degree reflecting the asymmetry of both TAP subunits. Exchanging the leucine or 
glycine (LSGGQ) in TAP1 fully abolished peptide transport. However, TAP complexes 
with equivalent mutations in TAP2 (LAAGQ) showed still residual peptide transport 
activity. Accordingly, mutations in ATP-binding site I (formed by Walker A and B motifs 
of TAP1 and C-loop of TAP2) are tolerated to a certain extent, whereas TAP complexes 
with the same mutations in site II are inactive. These findings are in agreement with 
Walker A mutations of TAP1 (site I) are still able to transport peptides, although with very 
low efficiency, whereas equivalent mutations at site  II interrupt peptide translocation 
(Karttunen et al., 2001; Lapinski et al., 2003). As all our C-loop mutants do neither alter 
the peptide nor ATP binding, we conclude that these mutations influence the ATP activity 
of TAP. These results are supported by the recent finding that an exchange the invariant 
glycine to alanine in the C-loop of TAP1 does not influence peptide binding but abrogates 
peptide transport via the TAP complex (Hewitt and Lehner, 2003). In addition, analogous 
P-gp mutants of the invariant glycine in the N- or C-terminal NBD show ATP binding, but 
not ATPase activity (Szakacs et al., 2001). Furthermore, in the maltose permease (MalK 
subunit), the pheromone transporter Ste6p, and CFTR, the exchange of the invariant 
glycine decreases the ATPase as well as transport activity (Browne et al., 1996; Ketchum 
et al., 2001; Li et al., 1996; Panagiotidis et al., 1993). The exchange of the invariant 
glycine of the C-loop (LSGGQ) reduces the ATPase activity of all ABC-transporters 
studied so far. Nevertheless, there are some subtle differences in the consequences induced 
by the mutations, which are marked by a total loss or strong decrease in catalytic activity. 
TAP mutants of the invariant glycine are non-equivalent, implying that the degenerated 
ATP-binding site I is less crucial for the transport function than site II. We conclude that 
C-loop mutants of TAP2, which contains a mutated ATP-binding site I but an intact site II, 
are still able to form an active NBD-dimer but with a strong decreased ATPase activity 
reflected in the strongly decreased transport rate. The equivalent mutation in the C-loop of 
TAP1 (a mutated site II) leads to an inactive transport complex. This model is supported by 
mutational studies of GlcV, the NBD of the glucose transporter of Sulfolobus solfataricus. 
The G144A mutant (LSGGQ) that cannot form homodimers, and the E166A mutant Chapter 5    Discussion 
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(putative catalytic base) are both ATPase inactive (Verdon et al., 2003). However, 
mixtures of both GlcV mutants can form dimers with 20% ATPase activity of wt GlcV, 
demonstrating that one active ATP binding site is sufficient for ATP hydrolysis.  
To decipher the origin of the asymmetry of the NBDs of TAP, we exchanged the C-
loops of TAP1 and TAP2. Comparable to the single-site mutants, all C-loop chimeras 
showed similar peptide and ATP binding activities. Strikingly, the C-loop controls the 
peptide transport efficiency: the chimera with two canonical C-loops showed the highest 
transport rate whereas the chimera with two degenerated C-loop sequences the lowest. 
TAP complexes with mixed C-loops transport peptides with almost identical efficiency. 
Based on the crystal structures of NBD dimers (Chen et al., 2003a; Hopfner et al., 2000; 
Smith et al., 2002b), it was postulated that the serine of the C-loop forming a hydrogen 
bond to the γ-phosphate of ATP is essential for ABC-protein function. This serine in the C-
loop is conserved in all human ABC-proteins, except for TAP2. However, here we provide 
evidence that this serine is not essential for TAP1 function. This observation is also 
supported by BeFx-trapping experiments, which demonstrated that both ATP-binding sites 
of TAP hydrolyze ATP in a peptide-specific manner, although the C-loop of TAP2 does 
not contain a serine residue (Chen et al., 2003b). The serine of the canonical C-loop may 
be at least partially involved in the timing of ATP hydrolysis and hence the asymmetry of 
TAP1 and TAP2. Similar results are most recently obtained for P-glycoprotein (Tombline 
et al., 2004). Mutation of the serine in the C-loop of P-glycoprotein to alanine in one of 
each NBD reduces ATPase activity to 66% and the double mutant possesses 3% ATPase 
activity of wt P-glycoprotein. In GlcV the serine of the C-loop is not essential for ATP 
hydrolysis (Verdon et al., 2003). The S142A mutant hydrolyzes ATP with 50% of the 
activity of wt GlcV. However, any other substitution of this highly conserved serine leads 
to an inactive protein. Furthermore, mutation of this serine residue to asparagine, 
isoleucine or arginine in the ATP-binding site II of CFTR results in cystic fibrosis (Cutting 
et al., 1990; Kerem et al., 1990). The same mutations in pheromone transporter STE6p 
drastically reduce secretion of mating a-factor (Browne et al., 1996). Also the conservative 
mutation, serine to cysteine reduces the ATPase activity of P-glycoprotein to 22% of wt P-
glycoprotein (Loo et al., 2002). The glycine residue (LSGGQ) is expected to have minor 
effects on the asymmetry because this residue is divergent not only in human ABC-
transporters (Fig. 4-8C) but also between human (LAAGQ) and rodent (LAVGQ) TAP2. Chapter 5    Discussion 
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The TAP mutants described herein provide information about the architecture of 
the C-loops. Exchange of the highly conserved glycine of the C-loop (LSGGQ) has severe 
effects on the transport activity. The monomeric structure of the GlcV mutant (G144A) 
shows within a resolution of 1.5 Å no conformational changes in the C-loop (Verdon et al., 
2003). By modeling the GlcV (G144A) dimer on the dimeric MJ0796 structure, it became 
evident that the methyl group of alanine causes steric hindrance with an oxygen of the γ-
phosphate of ATP as well as the side chain of serine in the Walker A motif of the opposite 
NBD (Verdon et al., 2003). Therefore, introducing any side chain at the position of the 
invariant glycine of the C-loop is believed to inhibit NBD dimer formation by steric 
hindrance. In the C-loop, the hydroxyl group of the serine forms a hydrogen bond with the 
γ- phosphate of ATP (Chen et al., 2003a; Smith et al., 2002b). Introduction of an alanine at 
this position does not seem to weaken the NBD dimer affinity, because transient GlcV 
dimers of S142A mutants could be detected by gel filtration in the presence of MgATP 
(Verdon et al., 2003). This finding supports the idea that the serine to alanine mutation in 
the C-loop reduces the ATPase activity, which prolongs dimer formation. Accordingly, we 
suggest that the peptide transport rate of TAP containing two degenerated C-loops is 
lowered by decreasing the rate of ATP hydrolysis and not the rate of dimer formation. The 
leucine of the C-loop points to a hydrophobic, buried environment. These hydrophobic 
interactions seem to stabilize the structure of the C-loop as introducing alanine instead of 
leucine drastically decreases the peptide transport activity of TAP. 
In summary, the C-loop is an essential motif that is involved in the functional 
asymmetry of the NBDs of the TAP complex. The substitutions of the invariant glycine or 
the leucine of the C-loop demonstrated the asymmetric behaviour of both ATP binding 
sites. These finding reveals that ATP-binding site  II is more important than site  I for 
catalytic activity of TAP. The serine residue in the C-loop is not essential for transport 
function. Moreover, the serine to alanine substitution induces an asymmetric behaviour of 
both NBDs potentially by slowing down the ATP hydrolysis rate. This may result in a 
prolonged NBD dimer formation. 
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5.3  Role of the acidic residue downstream of the Walker B motif 
EQ mutants of TAP were generated to identify a transition state with a low peptide-
binding affinity induced by ATP binding or hydrolysis. At 4°C, nucleotides showed no 
influence on the peptide-binding sites, while nucleotides binding to all TAP complexes 
containing mutated TAP2 induced a partial reduction of Bmax at 27°C. In addition, 
mutation of the putative catalytic base at both sites does not abolish the function of the 
TAP complex. 
It was proposed that transporters may employ a central binding site that is 
alternately exposed to each side of the membrane (Mitchell, 1957). Extended from this 
notion, an alternating access/binding site model has been proposed to explain the 
conformational coupling between the ABC domains and substrate-binding sites. In detail, 
it is believed that ABC transporters have to couple two distinct activities in order to 
mediate active extrusion of substrates: i) conformational changes in the nucleotide-binding 
domains induced by the binding and /or hydrolysis of ATP. ii) reorientation of substrate-
binding sites in the transmembrane domains with alternate exposure to each face of the 
membrane. Such alternating changes in the substrate-binding affinity facilitate the 
substrate binding to and release from the transporter (Davidson, 2002; Urbatsch et al., 2003; 
van Veen et al., 2000). A drastic decrease in substrate-binding affinity of MRP1, Pgp and 
LmrA in the transition state trapped by vanadate is an important support for this model 
(Qian et al., 2001; Sauna and Ambudkar, 2001; van Veen et al., 2000).  
So far, such a low affinity peptide-binding site of TAP has not been identified. In 
contrast to Pgp, TAP retains a high affinity peptide-binding site in a BeFx-trapped state. 
Previous studies have shown that EQ mutation of the NBDs arrest these proteins in two 
dimeric transition states, which sandwich two ATP or one ATP and one ADP, respectively 
(Janas et al., 2003; Moody et al., 2002; Verdon et al., 2003). Thus, we anticipated that TAP 
EQ mutants would shift from a high to low substrate-binding site in one of the transition 
states according to the alternating binding site model.  
In contrast to our expectation, peptide-binding ability seems not affected in the 
ATP sandwich state of the TAP complex. At 4°C, neither the Kd nor the Bmax has been 
changed by the nucleotides for all TAP constructs (Tab. 4-3), demonstrating binding of 
ATP or ADP does not influence the substrate-binding domain of these proteins. So far, 
biochemical studies on isolated EQ NBD mutants reveals that they all form dimers after Chapter 5    Discussion 
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ATP binding at 4°C and ATP hydrolysis is not required for this process (Janas et al., 2003; 
Moody et al., 2002; Orelle et al., 2003; Verdon et al., 2003). Accordingly, our results 
suggest that peptide-binding sites of double EQ mutants remain in a high affinity state 
when their NBDs are trapped in the dimeric conformation. Thus, we conclude that ATP-
induced dimerization of the NBDs does not induce the shift of the peptide-binding site 
from a high to a low affinity state. Nevertheless, we cannot exclude that the trapped 
dimerization state of the double EQ mutants (1DN/2EQ and 1DQ/2EQ) was still too 
transient to be probed by this assay. Moreover, it should be noted that so far the NBD 
dimerization upon ATP binding has only been observed in the studies of isolated NBDs, 
and direct evidence supporting the dimeric state in the full-length ABC transporters is still 
missing.  
Next, the peptide-binding affinity of TAP complexes in the second NBD dimeric 
state was investigated. The EQ mutant of NBDs of the MDL1 was shown to be locked in 
this state after hydrolysis of one of the two bound ATPs (Janas et al., 2003). After 
incubation of the TAP variants under transport condition to convert TAP into the ATP-
ADP dimeric state, TAP complexes containing mutated TAP2 (1wt/2EQ, 1DN/2EQ and 
1DQ/2EQ) exhibited a reduced peptide-binding sites by 20 %. This suggests that a fraction 
of proteins was not accessible to peptides upon interaction with nucleotides. Surprisingly, 
nucleotides at saturating concentrations could not induce a more drastic reduction. Two 
reasons might contribute to such a subtle effect: i) 20 nM of peptides failed to trigger the 
ATP hydrolysis of all proteins and further induces a complete response; ii) the trapped 
state is not stable and a large portion of TAP complexes still rest in the states which expose 
a high affinity site for peptides. Further experiments are needed to clarify these points. 
Since the 1wt/2EQ mutant behaves differently from its equivalent TAP1 mutants, it 
is tempting to speculate that only the EQ mutation in TAP2 is sufficient to trap the TAP 
complex in a low-affinity or peptide-inaccessible state in the presence of nucleotides. In 
the case of Pgp, it is believed that there are two ATP hydrolysis events in one full catalytic 
cycle. The first ATP hydrolysis event occurs randomly at one of the NBDs and induces a 
drastic decrease of substrate binding, while the second ATP hydrolysis sets the transporter 
back to the ground state (Sauna and Ambudkar, 2001). LmrA also contains two ATP 
hydrolysis events in one cycle, each hydrolysis event can trigger the transmembrane 
domain shifting from high to low affinity state (van Veen et al., 2000). Despite of the Chapter 5    Discussion 
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difference in these two findings, they both supported the notion that the ATP hydrolysis at 
either of the two NBDs has the potential to induce the conformation change in the 
transmembrane domain. By contrast, the NBDs of MRP1 displayed a distinct function in 
the ATP hydrolysis cycle (Hou et al., 2000; Hou et al., 2003). Only ATP binding and 
hydrolysis by NBD2 was required for MRP1 to switch from a high to low affinity 
substrate-binding site (Payen et al., 2003; Qian et al., 2001). The different behaviors of 
TAP1 and TAP2 single mutants suggested that the TAP complex alters its substrate-
binding site by a mechanism similar to that of MRP1.  
So far, ATP has been found to be absolutely required for the dimer formation of the 
EQ mutants of isolated NBDs of ABC transporters. It was surprising to observe that ADP 
also induced the alteration of the peptide-binding site in the TAP2 mutants. Thus, it is not 
clear whether ADP binding also induces a dimer formation of NBD in the full-length 
transporter or the dimerization of the NBDs does not occur concomitantly with the 
alteration of the peptide-binding site. Further investigations are required to identify how 
ATP and ADP induce conformational changes of the NBDs of the EQ mutants (1wt/2EQ, 
1DQ/2EQ and 1DN/2EQ) and subsequently the alteration of the peptide-binding site. 
Effects of mutating the putative catalytic base on the function of ABC transporters 
are not consistent. In most of the cases, the ATPase activity of isolated EQ NBDs almost 
abolished the ATPase activity (Janas et al., 2003; Moody et al., 2002; Orelle et al., 2003; 
Urbatsch et al., 2000). In cases of full-length ABC transporters, e.g. Pgp and BmrA, 
mutation one of the sites was sufficient to fully inhibit the substrate transport (Orelle et al., 
2003; Sauna et al., 2002). By contrast, Verdon et al. also showed that the EQ mutants of 
soluble GlcV retains 20% of ATPase activity (Verdon et al., 2003). Together with the 
observation of the TAP double mutants, it indicates that the acidic residue downstream of 
the Walker B motif is not essential for the function of some ABC transporters. 
Surprisingly, the TAP 1DN/2wt mutant still maintains full activity. This 
observation was again in line with the studies on MRP1, in which substitution of the 
aspartate in the NBD1 of MRP1 with a series of residues (e.g. serine, leucine, asparagine) 
only slightly decreases the drug transport activity (Payen et al., 2003). It should be noted 
that although TAP belongs to ABCB subfamily, TAP1 and TAP2 share common features 
with ABCC family members in respect to the highly conserved sequences: i) an aspartate 
downstream of the Walker B in the NBD1; ii) a non-conserved C-loops in the NBD2 (see Chapter 5    Discussion 
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appendix 9.2). These biochemical coincidences indicate that TAP might share common 
mechanism of ATP hydrolysis with the ABCC family members. Notably, the partial 
activity of EQ mutants also suggests that these proteins are not trapped in a stable 
transition state triggered by ATP binding and/or hydrolysis, which is likely the reason for 
the observed subtle reduction of Bmax. 
In parallel, it was observed that peptide transport by TAP double EQ mutants 
depends on the presence of divalent cations as strictly as for the wild type protein. 
According to the structure of BtuCD, it was proposed that the two NBDs dimerize upon 
ATP binding, which act as the power stroke for the substrate translocation (Locher et al., 
2002; Smith et al., 2002b). From this model, one can anticipate that peptide translocation 
by TAP EQ double mutants is only due to ATP binding even though removal of the acidic 
residues completely diminishes the catalytic activity. However, here we observed that TAP 
1DQ/2EQ mutant transport peptides in a divalent cation-dependent manner. It should be 
stressed that a divalent cation was not absolutely required for the EQ mutants to carry out 
ATP binding and subsequent dimerization (Janas et al., 2003; Moody et al., 2002; Verdon 
et al., 2003). Thus we conclude that TAP EQ utilizes the divalent cation for ATP 
hydrolysis rather than only ATP binding.  
In summary, the putative catalytic bases are not essential for ATP hydrolysis by 
TAP transporter. Double EQ mutants bind peptides in the presence of ATP at 4 °C 
indicating that ATP binding, followed by dimerization of the NBDs does not affect the 
peptide-binding site. These mutants bearing mutated TAP2 tend to switch to a 
conformation in which the peptide-binding sites are not accessible during the ATP 
hydrolysis cycle. Further studies on the TAP EQ proteins may reveal more information 
about the stage of catalytic process in which the peptide-binding site is altered. 
Finally, based on the knowledge about other ABC-transporters as well as our 
findings we propose the following working model for TAP: Peptide and ATP bind 
independently to TAP. In the absence of peptide the NBDs are fixed in a monomeric state 
by interactions between TMD and NBD. Binding of peptide weakens these interactions 
allowing the ATP-loaded NBDs to dimerize. The NBD-dimer is stabilized preferentially by 
interactions within the ATP binding site II. Two ATPs are then hydrolyzed sequentially at 
both ATP-binding sites. Peptide is delivered to the ER probably after the first ATP 
hydrolysis at ATP-binding site II. The introduction of a negative charge by ATP hydrolysis Chapter 5    Discussion 
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or the release of inorganic phosphate forces the dissociation of the NBDs, which reset the 
protein for the next cycle. For efficient transport, ATP hydrolysis at both nucleotide-
binding sites takes place to destabilize the NBD-dimer. Therefore, two ATP are hydrolysed 
per transported peptide under normal condition. However, ATP hydrolysis at ATP binding 
site II is sufficient to dissociate the NBD-dimer albeit with a much slower dissociation rate 
constant. This explains why mutation at ATP-binding site I but not at site II could retain 
residual peptide transport activity. 
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6. Abbreviations 
 
ABC  ATP binding cassette 
ADP   adenosine diphosphate 
ATP   adenosine triphosphate 
CFTR  cystic fibrosis transmembrane conductance regulator 
CTL cytotoxic  T-lymphocyte 
DTT   1,4-dithio-DL-threitol 
EDTA   ethylenediaminetetraacetic acid 
EGTA  
ethylene glycol-bis(2-aminoethylether)-N,N,N´,N´-
tetraacetic acid 
ER endoplasmic  reticulum 
HEPES   N-(2-hydroxyethylpiperazine)-N´-2-ethanesulfonic acid 
ICD intracellular  domain 
IPTG   isopropyl β-D-thiogalactopyranoside 
MDL  multi-drug resistance like protein 
MHC  major histocompatibility complex  
MRP  multi-drug resistant protein 
NBD nucleotide-binding  domain 
PAGE   polyacrylamide gel electrophoreseis 
PBS phosphate-buffered  saline 
Pgp P-glycoprotein 
SDS   sodium dodecyl sulphate 
Sf9  Spodoptera frugiperda 9 
SUR sulfonylurea  receptor 
TAP  transporter associated with antigen processing 
TCR T-cell  receptor 
TGN  trans-Golgi network 
TMD transmembrane  domain 
Tris   tris (hydroxymethyl)aminomethane 
wt   wild type Chapter 7    Summary 
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7. Summary 
 
The transporter associated with antigen processing (TAP) plays a pivotal role in the 
adaptive immune response against virus-infected or malignantly transformed cells. As 
member of the ABC transporter family, TAP hydrolyzes ATP to energize the transport of 
antigenic peptides from the cytosol into the lumen of the endoplasmic reticulum. TAP 
forms a heterodimeric complex composed of TAP1 and TAP2 (ABCB2/3). Both subunits 
contain a hydrophobic transmembrane domain and a hydrophilic nucleotide-binding 
domain. The aim of this work was to study the ATP hydrolysis event of the TAP complex 
and gain further insights into the mechanism of peptide transport process. 
To analyze ATP hydrolysis of each subunit I developed a method of trapping 8-
azido-nucleotides to TAP in the presence of phosphate transition state analogs followed by 
photocross-linking, immunoprecipitation, and high-resolution SDS-PAGE. Strikingly, 
trapping of both TAP subunits by beryllium fluoride is peptide-specific. The peptide 
concentration required for half-maximal trapping is identical for TAP1 and TAP2 and 
directly correlates with the peptide-binding affinity. Only background levels of trapping 
were observed for low affinity peptides or in the presence of the herpes simplex viral 
protein ICP47, which specifically blocks peptide binding to TAP. Importantly, the peptide-
induced trapped state is reached after ATP hydrolysis and not in a backward reaction of 
ADP binding and trapping. In the trapped state, TAP can neither bind nor exchange 
nucleotides, whereas peptide binding is not affected. In summary, these data support the 
model that peptide binding induces a conformation that triggers ATP hydrolysis in both 
subunits of the TAP complex within the catalytic cycle. 
The role of the ABC signature motif (C-loop) on the functional non-equivalence of 
the NBDs was investigated. The C-loops of TAP transporter contain a canonical C-loop 
(LSGGQ) for TAP1 and a degenerated ABC signature motif (LAAGQ) for TAP2. 
Mutation of the leucine or glycine (LSGGQ) in TAP1 fully abolished peptide transport. 
TAP complexes with equivalent mutations in TAP2 showed however still residual peptide 
transport activity. To elucidate the origin of the asymmetry of the NBDs of TAP, we 
further examined TAP complexes with exchanged C-loops. Strikingly, the chimera with 
two canonical C-loops showed the highest transport rate whereas the chimera with two 
degenerated C-loops had the lowest transport rate, demonstrating that the ABC signature Chapter 7    Summary 
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motifs control the peptide transport efficiency. All single-site mutants and chimeras 
showed similar activities in peptide or ATP binding, implying that these mutations affect 
the ATPase activity of TAP. In addition, these results prove that the serine of the C-loop is 
not essential for TAP function, but rather coordinates, together with other residues of the 
C-loop, the ATP hydrolysis in both nucleotide-binding sites. 
To study the coupling between the ATP binding/hydrolysis and the peptide binding, 
the putative catalytic bases of the TAP complex were mutated to generate the so-called EQ 
mutants. The mutations did not influence the peptide-binding ability. Dimerization of the 
NBDs of EQ mutants upon ATP binding does not alter the peptide binding property. At 
27°C, both ATP and ADP could induce the loss of peptide-binding ability (Bmax) only in 
the variants bearing a mutated TAP2. Further studies are required to deduce at which stage 
in the catalytic cycle the peptide-binding site is affected. In addition, mutation of the 
putative catalytic base of both subunits showed a magnesium-dependent peptide transport 
activity, demonstrating these mutants did not abolish the ATP hydrolysis. Thus, the 
function of this acidic residue as the catalytic base is not likely to be universe for all ABC 
transporters. 
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8. Zusammenfassung 
 
Der menschliche Organismus ist in seiner Umgebung einer Vielzahl von Pathogenen 
ausgesetzt. Aufgrund dieses Selektionsdrucks hat sich im Laufe der Evolution bei den 
Vertebraten das adaptive Immunsystem entwickelt. Dieses lässt sich in die humorale und 
die zelluläre Immunität unterteilen. Die humorale Immunantwort beschränkt sich auf die 
Produktion von Antikörpern durch B-Lymphozyten. Auftretende antigene Strukturen 
werden durch diese Immunglobuline markiert und nachfolgend beseitigt.  
Die zelluläre Immunantwort hingegen wird über T-Lymphozyten vermittelt. Innerhalb der 
Zelle werden Proteine durch das Proteasom degradiert. Die generierten Peptide werden im 
Komplex mit MHC I (major histocompatibility complex class I) Molekülen den CD8
+-T-
Lymphozyten präsentiert. Die Erkennung eines antigenen Peptids (z.B. viraler oder 
Tumor-assoziierter Herkunft) führt zur Zerstörung einer infizierten oder entarteten Zelle. 
Der Prozess der Generierung und MHC I-vermittelten Präsentation von Peptiden wird als 
Antigenprozessierung bezeichnet. TAP (transporter associated with antigen processing) 
erfüllt im Rahmen dieses Prozesses eine wichtige Aufgabe. Die durch das Proteasom 
produzierten Peptide werden von TAP aus dem Zytoplasma in das Lumen des 
Endoplasmatischen Retikulums (ER) transportiert. Nachfolgend werden diese Peptide auf 
MHC I Moleküle geladen und über den Golgi-Apparat auf der Zelloberfläche präsentiert.  
TAP gehört zur Familie der ABC (ATP binding cassette)-Transporter, welche ATP-
abhängig ein breites Spektrum an Substanzen über eine Membran transportieren. TAP 
formt einen Heterodimer bestehend aus TAP1 und TAP2. Jede Untereinheit wird aus einer 
N-terminale Transmembrandomäne (TMD) gefolgt von einer Nukleotidbindungsdomäne 
(NBD) gebildet. TAP1 und TAP2 werden auch als sogenannte half-size transporter 
bezeichnet. Die TMDs beider Untereinheiten bilden zusammen die Peptidbindungsstelle 
und formen die Translokationspore. TAP transportiert vornehmlich Peptide mit einer 
Länge von 8-16 Aminosäuren. Die Bindungsselektivität der Peptide wird durch die ersten 
drei N-terminalen und die letzte C-terminale Aminosäure bestimmt.  
Die zytoplasmatischen NBDs sind die Motordomänen von ABC-Transportern, die ATP 
hydrolysieren und die für den Transport benötigte Energie bereitstellen. Beide NBDs 
enthalten die für die Bindung und Hydrolyse von ATP essentiellen Walker A-, Walker B- 
und C-Loop-Motive. Diese Motive sind unter allen ABC-Transportern hoch konserviert. Chapter 8    Zusammenfassung 
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Die in der Walker B-Sequenz befindlichen Aminosäuren Asp688 (TAP1) und Glu632 
(TAP2) werden als katalytische Basen bezeichnet, da sie wahrscheinlich ein 
Wassermolekül polarisieren, welches infolge dessen das ￿-Phosphat des ATPs nukleophil 
angreift. 
Im Verlauf dieser Arbeit erschienen einige biochemische und biophysikalische 
Publikationen, die zeigten, dass die NBDs von ABC-Transportern in Anwesenheit von 
ATP Dimere bilden. Dabei werden an der Grenzfläche der zwei NBDs zwei Moleküle ATP 
komplexiert. An der Bindung eines ATP Moleküls sind die Walker A/B Motive und der C-
Loop der benachbarten NBD beteiligt. Allerdings geht aus diesen Arbeiten nicht hervor, ob 
beide Motordomänen während des Substrattransportes katalytisch aktiv sind. Daher steht 
im Fokus der Forschung die Frage nach dem molekularen Mechanismus der Interaktionen 
beider NBDs innerhalb eines Transportzyklus. Frühere Studien an TAP hatten gezeigt, 
dass der Peptidtransport strikt mit der Peptidbindung und der Hydrolyse von ATP 
gekoppelt ist. Für den Peptidtransport ist die Anwesenheit beider NBDs essentiell. 
Allerdings wurde die ATPase-Aktivität der einzelnen NBDs bisher nicht nachgewiesen. 
Deswegen wurde im ersten Teil dieser Doktorarbeit der Frage nachgegangen, ob beide 
NBDs von TAP während des Transportprozesses katalytisch aktiv sind.  
Aus diesem Grund wurde im Rahmen dieser Arbeit zuerst eine Methode etabliert, um die 
katalytische Aktivität der einzelnen Untereinheiten zu analysieren. Dabei werden 8-azido-
Nukleotide mittels ATPase Inhibitoren fest an TAP gebunden. Diese Gruppe von ATPase-
Inhibitoren stellen Phosphatanaloga (z.B. BeFx, ScFx oder Vi) dar, welche die Position des 
abgespaltenen ￿-Phosphats des ATP einnehmen, wodurch sich ein stabiler Komplex aus 
Mg•8-Azido-ADP und einem Phosphatanalogon bildet. Die Komplexierung der Nukleotide 
mittels dieser Inhibitoren erfolgt nur nach ATP-Hydrolyse, womit eine Möglichkeit besteht, 
die katalytische Aktivität der einzelnen Untereinheiten zu verfolgen. Nach der Bindung des 
8-Azido-Nukleotids wird durch die Bestrahlung der Probe mit UV-Licht eine kovalente 
Verknüpfung mit der NBD erzielt. Die TAP-Untereinheiten werden daraufhin 
immunpräzipitiert, durch hochauflösende PAGE separiert und über Autoradiographie 
visualisiert.  
Mit dem Inhibitor BeFx konnte 8-Azido-ADP effizient in den NBDs sowohl von TAP1 als 
auch TAP2 fest gebunden werden. Die Komplexierung von ADP durch BeFx wird durch 
die Anwesenheit von Peptid stimuliert. Somit scheint sowohl TAP1 als auch TAP2 peptid-Chapter 8    Zusammenfassung 
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abhängig ATP zu hydrolysieren. Dabei korreliert die halbmaximale Stimulation der 
ATPase-Aktivität beider Untereinheit mit der Peptidaffinität. In Abwesenheit von Peptiden 
oder in Gegenwart des viralen TAP-Inhibitors ICP47 (Inhibition der Peptidbindung) wurde 
bei beiden NBDs nur eine geringe Hintergrund-Aktivität detektiert. In dem Mg•ADP•BeFx 
komplexierten Zustand kann TAP weder Nukleotide binden noch austauschen. Allerdings 
ist die Peptidbindung in diesem fixierten Zustand nicht beeinflusst. Basierend auf diesen 
Daten kann festgestellt werden, dass beide Untereinheiten des Peptidtransporters ATP in 
einer peptidabhängigen Weise hydrolysieren. 
Studien an Walker A Mutanten zeigen, dass beide Untereinheiten von TAP während des 
Transportprozesses asymmetrisch agieren. Ein Grund für diese funktionelle Asymmetrie 
könnte in den unterschiedlichen Sequenzen der C-Loops von TAP1 und TAP2 liegen. 
Während TAP1 (LSGGQ) die kanonische C-Loop-Sequenz besitzt, weist TAP2 (LAAGQ) 
einen sogenannten degenerierten C-Loop auf. Um den Einfluss der unterschiedlichen C-
Loops auf die funktionelle Asymmetrie von TAP aufzuklären, wurden im Rahmen dieser 
Arbeit Mutationsstudien an den C-Loops durchgeführt. Zum einen wurden 
Aminosäurenreste ausgetauscht, welche sowohl in TAP1 (LSGGQ, mutierte 
Aminosäurenseitenketten sind unterstrichen) als auch TAP2 (LAAGQ) vorhanden sind. 
Die generierten C-Loop-Mutanten (1LA/2wt, 1GV/2wt, 1GD/2wt, 1wt/2LA, 1wt/2GV und 
1wt/2GD) werden in gleichem Maße in Sf9-Insektenzellen exprimiert wie das Wildtyp-
Protein (wt-TAP). Weiterhin konnten keine signifikanten Unterschiede bezüglich der 
Peptidaffinität und der ATP-Bindung festgestellt werden. Allerdings weisen die Mutanten 
im Vergleich zum wt-TAP eine veränderte Transportaktivität auf. TAP-Komplexe, bei 
denen das Leucin bzw. Glycin in TAP1 (LSGGQ) mutiert wurde, zeigen keinen 
Peptidtransport. Dagegen besitzen TAP-Komplexe mit den entsprechenden Mutationen in 
TAP2 (LAAGQ) eine erniedrigte Transportaktivität. Dadurch wird jedoch verdeutlich, 
dass TAP1 und TAP2 funktional nicht identisch sind.  
Durch den Austausch der C-Loops zwischen TAP1 und TAP2 konnte gezeigt werden, dass 
die C-Loops zumindest teilweise für die funktionelle Asymmetrie der beiden 
Untereinheiten verantwortlich sind. Dabei transportieren TAP-Chimären mit zwei 
kanonischen C-Loops (LSGGQ) Peptide mit einer höheren Effizienz als TAP-Komplexe 
mit einem kanonischen C-Loop (LSGGQ) und einem degenerierten C-Loop (LAAGQ). Im 
Vergleich dazu transportieren TAP-Chimären mit zwei degenerierten C-Loops Peptide mit Chapter 8    Zusammenfassung 
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geringster Effizienz. Die Peptidbindungs- und Nukleotidbindungseffizienz der TAP-
Chimären wurden nicht beeinflusst, so dass diese Mutationen wahrscheinlich 
ausschließlich die ATPase Tätigkeit verändern. Desweiteren belegen diese 
Mutationsstudien, dass das konservierte Serin des C-Loops (LSGGQ) für die katalytische 
Aktivität nicht essentiell ist. Dieses Serin kommt in allen menschlichen ABC-Transportern 
außer TAP2 vor und bildet eine Wasserstoffbrücke zum ￿-Phosphat von ATP aus. 
Folglich beeinflussen Mutationen des hoch konservierten Serins des C-Loops die ATP-
Hydrolysegeschwindigkeit und Mutationen des Leucins und Glycins (LSGGQ) die 
Dimerisierung der NBDs während des Transportzyklus. Offensichtlich destabilisieren 
Mutationen im kanonischen C-Loop von TAP1 das NBD-Dimer stärker als die 
äquivalenten Mutationen in TAP2. Folglich trägt die ATP-Bindungsstelle II (Walker A/B-
Motiv von TAP2 und C-Loop von TAP1) mehr zur Dimerbildung bei als die ATP-
Bindungsstelle I.  
Es wird vermutet, dass die TMD von ABC-Transportern während des katalytischen Zyklus 
Konformationsänderungen durchlaufen, wodurch die Substrataffinität stark verringert wird. 
Diese strukturelle Änderung erleichtert die Freisetzung des Substrats auf der 
gegenüberliegenden Seite der Membran. Im letzten Teil dieser Arbeit wurde daher 
versucht, einen Zustand von TAP zu identifizieren, der induziert durch ATP-Bindung oder 
ATP–Hydrolyse eine erniedrigte Peptidaffinität aufweist. Da im TAP-Komplex ein solcher 
Zustand bisher nicht nachgewiesen werden konnte, wurden im Walker B-Motiv die sauren 
Aminosäuren Asp688 in TAP1 und Glu632 in TAP2 gegen Asparagin bzw. Glutamin 
ersetzt. Studien an anderen ABC-Transportern oder isolierten NBDs haben gezeigt, dass 
die Mutation der katalytischen Base zu einem Glutamin die ATP-Hydrolyse inhibiert und 
sich in Gegenwart von ATP ein stabiler NBD-Dimer bildet. Es wird postuliert, dass solch 
ein NBD-Dimer einen Übergangszustand im Transportzyklus von TAP mit stark 
erniedrigter Substratspezifität darstellt. Die Einzel- oder Doppelmutation der Aminosäuren 
Asp688 und Glu632 beeinflussen im Vergleich zum wt-TAP weder Expressionsrate noch 
Peptidaffinität. Überraschenderweise transportieren alle Mutanten Peptide. Selbst die 
Doppelmutanten, bei denen beide katalytischen Basen zu Asparagin oder Glutamin mutiert 
wurden, zeigten im Vergleich zu wt-TAP noch eine 30%ige Transportaktivität. Auch bei 
diesen Mutanten ist der Peptidtransport von der ATP-Hydrolyse abhängig, da divalente 
Kationen einen essentiellen Kofaktor darstellen. Daher scheint zumindest in TAP das Chapter 8    Zusammenfassung 
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katalytische Wassermolekül nicht nur durch die postulierte Base sondern auch durch 
andere Aminosäureseitenketten polarisiert werden zu können.  
Die Hydrolyse des ATPs und nicht die Dimerisierung der Motordomänen liefert die 
Energie für den Peptidtransport, da bei diesen TAP-Mutanten unter Bedingungen, unter 
denen ATP-Hydrolyse nicht möglich ist, durch Zugabe von ATP keine Änderung der 
Peptid-Affinität festgestellt werden konnte.   
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9. Appendix 
9.1   Sequence alignment of human ABC transporters 
9.1.1 Walker  A 
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9.1.2  Walker B and C-loop 
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9.2 Vector  maps 
9.2.1 pFastBacDual 
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